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Summary  
(English) 
 
Multiple sclerosis (MS) is a chronic, inflammatory and demyelinating disorder of the central nervous 
system. Although demyelination is still a characteristic entity, it has become increasingly apparent in 
recent years that substantial axonal destruction and neuronal loss are equally important features. The 
frequent involvement of grey matter structures has received new impetus. Studies on the pathogenesis 
of grey matter lesions suggest that its underlying disease mechanisms are unique. Less marked 
microglia activation in grey compared to white matter lesions is obvious but underlying mechanisms 
are poorly understood. Adequate animal models are a likewise powerful and irreplaceable tool to study 
disease pathogenesis. In order to serve as a useful model, it should be similar in its aetiology or 
phenotype. The recognition of the importance of grey matter pathology in MS did lead to the desire for 
animal models that display grey matter damage. Within the scope of the presented thesis, I 
characterized the toxic cuprizone model with a special focus on grey matter pathology. This work is 
not confined to descriptive changes but makes a comparison between the model itself and MS. In 
recent years the contribution of innate immune cells in mediating MS pathogenesis is being 
appreciated. We were able to show that histopathological hallmarks of MS are closely mirrored by the 
cuprizone model. Furthermore, our studies clearly demonstrate that the magnitude of microglia 
activation is related to the amount of myelin debris during a demyelination event. Thus, the lower 
inflammatory infiltrate of grey matter lesion is not related to a unique grey matter cytoarchitecture that 
makes it more resistant to inflammation. Differences in myelination account for observed regional 
differences.  
The second part of this thesis deals with one of the most effective repair mechanisms in the central 
nervous system, i.e. remyelination.  A better understanding of the remyelination processes in MS and 
possible reasons for its failure is required. We created lesions with either robust or impaired 
endogenous remyelination capacity. Lesions were analyzed for mRNA expression levels by gene-chip 
arrays. One finding was the predominance of immune and stress response factors in the group of genes 
which were classified as remyelination-supporting factors. We further demonstrate that lesions with 
impaired remyelination capacity show weak expression of the radial-glia cell marker brain lipid 
binding protein (BLBP) whereas expression of this marker protein is high in lesions with marked 
remyelination. The expression of BLBP in activated astrocytes correlates with the presence of 
oligodendrocyte progenitor cells. Highest numbers of BLBP-expressing astrocytes were evident in 
lesions of early MS whereas significantly less are present in tissue samples from patients with long 
disease duration. Transfection experiments show that BLBP regulates growth factor expression in U87 
astrocytoma cells. In conclusion, we provide evidence that expression of BLBP in activated astrocytes 
orchestrates remyelination. 
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(German) 
 
Die Multiple Sklerose (MS) ist eine chronisch entzündliche Entmarkungserkrankung des Zentralen 
Nervensystems. Obwohl der Verlust der Myelinscheide auch heute noch ein zentraler Bestandteil der 
pathologischen Diagnosestellung darstellt zeigen sich auch Schäden im Bereich der grauen Substanz, 
die Nervenzellkörper enthält. Das Fortschreiten der Behinderung der Patienten hängt wesentlich von 
der Schädigung dieser grauen Substanz ab. Es wird vermutet, dass sich die zu Grunde liegenden 
Mechanismen der Gewebedestruktion in weißer und grauer Substanz unterscheiden. Die 
Entzündungsherde in der grauen Substanz sind meist weniger stark ausgeprägt.  
Tiermodelle sind unersetzbare Werkzeuge zum erforschen neuer therapeutischer Ansätze. Vor allem 
der „graue“ Aspekt der MS wurde bisher in Tiermodellen nur unzureichend untersucht. Im Rahmen 
der vorgelegten Arbeit charakterisierten wir das sog. „Cuprizone“ MS Modell. Sowohl die Beteiligung 
der grauen Substanz als auch regionale Unterschiede der Mikroglia-Aktivierung standen im 
Mittelpunkt meiner Untersuchungen. Des Weiteren wurden vergleichende Studien zur humanen 
Pathologie durchgeführt. Wir können zeigen, dass wesentliche Aspekte bei MS durch das Cuprizone 
Tiermodell repräsentiert werden. Die gängige Vermutung, dass geringer ausgeprägte 
Entzündungsherde der grauen Substanz auf zytoarchitektonische Besonderheiten zurück zu führen 
sind konnten teilweise widerlegt werden. Die Menge an anfallenden Myelin Abbauprodukten im 
Rahmen einer akuten Demyelinisierung scheinen vielmehr eine wichtige Rolle zu spielen.  
Zugrundeliegende Mechanismen des Wiederaufbaus von Markscheiden nach Demyelinisierung ist ein 
weiterer Schwerpunkt dieser Arbeit. Axonale Protektion ist eine der großen Herausforderungen bei der 
Behandlung demyelinisierender Erkrankungen, allen voran bei chronischen Verlausformen der MS. 
Remyelinisierung spielt in diesem Zusammenhang eine entscheidende Rolle. Es handelt sich hierbei 
um einen höchst effektiven Reparaturmechanismus des Zentralen Nervensystems der aus noch nicht 
geklärter Ursache bei MS Patienten im Krankheitsverlauf zum Erliegen kommt. In unseren Studien 
benutzten wird das toxische Cuprizone Demyelinisierungsmodell. Ein entscheidender Vorteil dieses 
Modells besteht in der Möglichkeit Läsionen mit und ohne endogener Remyelinisierungskapazität 
generieren zu können. Mit Hilfe der Affymetrix Array Technologie konnten wir etliche Faktoren 
identifizieren, die im Rahmen des Aufbaus entmarkter Axone von Bedeutung sind. Unsere Ergebnisse 
deuten darauf hin, dass ruhende Astrozyten im Rahmen der Demyelinisierung zu radialen-Glia 
ähnlichen Zellen de-differenzieren, um dann im Prozess der Remyelinisierung eine entscheidende 
Rolle zu spielen. Die Expression von Fettsäure-bindenden Proteinen wie BLBP scheint wichtig. 
Sowohl im Tiermodell als auch bei MS korreliert das BLBP Expressionsniveau positiv mit der 
Remyelinisierungspotenz. Durch stabile Transfektion konnten wir ausserdem aufzeigen, dass BLBP 
direkt an der Expression verschiedener Wachstumsfaktoren von Astrozyten beteiligt ist. Dieser Teil 
der vorgelegten Arbeit leistet einen wesentlichen Beitrag zu einem besseren Verständnis der Rolle von 
Astrozyten bei Remyelinisierung.  
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Abbreviations 
AA     arachidonic acid 
AD     Alexander disease  
AQP4     aquaporin-4  
BBB     blood-brain barrier  
BCA     bicinchoninic acid 
BLBP     brain lipid binding protein 
CC     corpus callosum 
CNPase    2',3'-cyclic nucleotide 3' phosphodiesterase 
CNS     central nervous system 
DHA     docosahexaenoic acid  
EAE     experimental autoimmune encephalomyelitis 
EBV     Epstein-Barr-Virus 
FABP     fatty acid binding protein 
FCS     fetal calf serum 
FGF2     fibroblast growth factor 2  
Fig(s)     figure(s) 
GFAP     glial fibrillary acidic protein  
H&E     hematoxylin and eosin  
HLA     human leukocyte antigen 
HPRT     hypoxanthine phosphoribosyltransferase 1 
IHC     immunohistochemistry 
LFB/PAS    Luxol Fast Blue and Periodic Acid Schiff  
MAG     myelin-associated glycoprotein 
MOBP     myelin-associated oligodendrocyte basic protein  
MOG     myelin oligodendrocyte glycoprotein  
MRI(s)     magnetic resonance imaging(s)  
MS     multiple sclerosis 
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PDGFα     platelet-derived growth factor alpha polypeptide  
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PPAR     peroxisome proliferator-activated receptor  
PP-MS     primary progressive multiple sclerosis 
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ROI     region of interest 
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rtPCR     Reverse-transcription polymerase chain reaction  
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TNFα     tumor necrosis factor-α 
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General Introduction 
 
1. Multiple sclerosis  
 
1.1 General remarks 
Multiple sclerosis (MS), a chronic inflammatory and demyelination disease, was first indentified as a 
separate neurological disorder by the French neurologist Jean-Martin Charcot, and is the most 
common disorder of the central nervous system (CNS) in young adults. Brain inflammation is 
associated with lesions appearing typically in plaques within the white matter. Recent 
histopathological studies, however, convincingly show that grey matter regions are equally affected. 
Women are affected more often than men [1]. The disease typically becomes clinically apparent 
between the ages of 20 and 40 years, although, it can begin either earlier or later in life. In Canada, 
Europe and the United States the prevalence ranges from 100-200 cases per 100,000 population. MS 
classically starts with visual problems or tingling sensations, however, due to the chronic nature of this 
disease, many patients develop other deficiencies such as impairment of motor functions, impairment 
of cognitive functions or an imbalance of the autonomic nervous system [2].  
 
1.2 Clinical aspects of the disease 
MS appears in several courses with new symptoms either in discrete episodes (relapsing remitting 
form) or slowly accumulating over time (progressive form). Most patients are first diagnosed with 
relapsing–remitting MS (RR-MS). This disease stage is characterized by self-limited attacks of 
neurological dysfunction. Attacks develop acutely, evolving over days to weeks. Over the next several 
weeks to months, the majority of patients experience a recovery of function that is often, but not 
always, complete. In between attacks the patient is neurologically and symptomatically stable. At later 
disease stages, most patients enter the secondary-progressive stage. This second clinical course, 
secondary progressive MS (SP-MS), begins as RR-MS but, at some point, the attack rate is reduced 
and the course becomes characterized by a steady deterioration in function, unrelated to acute attacks. 
This type of MS, which ultimately develops in approximately 80% of RR-MS patients, causes the 
greatest amount of irreversible neurological disability. Primary progressive MS (PP-MS) affects about 
15% of people diagnosed with MS. It is called this because from the first (primary) symptoms it is 
progressive. Symptoms gradually get worse over time, rather than appearing as sudden attacks 
(relapses) [1-3]. 
 
1.3 Aetiology 
Although the actual cause of MS remains to be elucidated, it is thought that genetic environmental 
factors contribute to the development of the disease. The genetic contribution is mainly restricted to 
the human leukocyte antigen (HLA) region. Heterozygosity or homozygosity for the HLA-
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DRB1*1501 allele, for example, increase the susceptibility of MS by 3.4-fold or 7.5-fold respectively 
[4]. Non-HLA genetic risk factors are polymorphisms in the interleukin-7 receptor gene [5], in the 
interleukin-2 receptor gene [6] or in the 3’ untranslated region of the interleukin-23 gene [7]. Another 
important factor appears to be certain environmental factors such as sunlight exposure, infections and 
smoking. The higher incidence of MS in countries more distant from the equator supports the idea that 
sunlight somehow influences the development of MS. In addition, studies with identical twins showed 
that higher exposure during childhood decreases the risk of getting MS [8]. This effect might be 
attributed to vitamin D. As shown by Munger et al. and others, high circulating levels of vitamin D 
were associated with a lower risk of MS [9, 10]. Another environmental factor that has been 
implicated in the aetiology of MS is the exposure to microbial or viral infections, such as Epstein-Barr 
virus (EBV). Almost all MS patients are seropositive for EBV and the risk to develop MS is higher in 
persons with a symptomatic EBV-infection or in people with high titres of anti-EBV antibody [11]. 
The idea that an infection agent could be linked to MS pathogenesis arose from studies where 
researchers have discovered epidemics of MS. There were four outbreaks in the Faroe Islands over a 
40 year period after World War II. Interestingly, there were almost no reported cases of MS among 
residents of the Faroe Islands before 1943. Since the islands were occupied by British troops, 
researchers believe the soldiers unknowingly brought a virus or bacteria with them during their 
occupation. But this theory has not been definitely proven, just like no other virus has been proven to 
cause MS. 
 
1.4 Therapeutic options   
For a long period, MS therapy was restricted to the acute treatment of severe relapses using 
immunosuppressive drugs, basically the corticosteroide (methyl)-prednisolone. Corticosteroids can 
decrease the inflammatory response by dampening the inflammatory cytokine cascade, inhibiting the 
activation of T cells, decreasing the extravasation of immune cells into the CNS, facilitating the 
apoptosis of activated immune cells, and, indirectly, by decreasing the cytotoxic effects of nitric oxide 
and tumor necrosis factor-α (TNFα ) [12]. Other therapeutic options in MS are the so called “disease-
modifying agents”. These drugs are prescribed to decrease the amount of clinical-detectable relapses 
during the relapsing phase of the disease and thus “modify” the clinical disease course. It is 
noteworthy that while the disease modifying therapies help RR-MS patients they are not effective for 
PP-MS patients [13], suggesting that in progressive disease, irrespective of being SP-MS or PP-MS, 
autoimmunity plays a minor role.  
 
1.5 Relevant animals models in MS research 
Animal models play an important role in the investigation of fundamental disease mechanism as well 
as in testing the efficacy of novel compounds or therapeutic regimens for use in MS. Since the 
histopathological hallmark of MS is loss of the nerve’s myelin sheath, i.e. demyelination, destruction 
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of myelin and oligodendrocyte loss are key features of most animal models used in the context of MS 
research. Demyelination in the CNS can be induced by viruses [14], chemicals [3, 15], or by 
sensitization with certain CNS proteins resulting in experimental autoimmune encephalomyelitis 
(EAE). Recently, spontaneous EAE models have become available by generating transgenic mice with 
myelin-specific T cell receptors and/or immunoglobulins directed against myelin antigens [16].  
 
1.6 Neuropathology 
Post-mortem tissue is widely used to study which molecular and cellular mechanisms are involved in 
the development of MS lesions. The histopathological hallmarks of the lesion are inflammation, 
demyelination and axonal degeneration. Using general histological methods such as haematoxylin and 
eosin (H&E) or Kluver-Barrera/luxol fast blue (LFB) stain in combination with 
immunohistochemistry (IHC) for myelin and human leukocyte antigen (HLA)-DR antigens (such as 
anti-LN3 antibodies), lesions can be classified into several stages. The lesion classification used in this 
thesis is that of Bö and Trapp, modified by De Groot and van der Valk [17]. According to the 
distribution of inflammatory cells and the presence or absence of myelin, five lesion stages can be 
discriminated: 
 
 
 
- Pre-active: the white matter contains activated microglial cells (strongly positive for HLA-
DR), however, there is no demyelination (figs. 1A/B). 
- Active demyelinating: the white matter area is hypercellular due to macrophages and/or 
microglia which are phagocytosing myelin sheaths, giving them a so called “foamy” 
appearance (fig. 1D). The presence of granules within macrophages that stain positive for 
particular myelin antigens, such as myelin associated glycoprotein (MAG) or proteolipid 
protein (PLP), or stain positive for chemical stains, such as LFB, indicate recent phagocytosis.  
- Chronic active: the lesion contains a hypocellular centre (fig. 1G) and a hypercellular rim (fig. 
1F) with myelin-containing macrophages indicating ongoing demyelination at the lesion edge 
and complete demyelination with cessation of inflammatory processes in the centre of the 
lesion.  
- Chronic inactive: the lesion is hypocellular although some residual inflammatory activity 
might be present at the borders of the lesion (not shown).  
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Figure 1 
Appearance of preactive, active and chronic-active lesion in LFB, anti-PLP and anti-LN3 stained sections is presented. Note 
focal accumulation of LN3-expressing microglia (B) in the normal appearing white matter tissue (A), characteristic for 
preactive lesions. (C) shows focal loss of PLP-immunoreactivity. The lesion centre is indicated by a star, the lesion rim by 
the arrow. Arrowhead indicates the so called “periplaque white matter” with a normal appearance in routine myelin stains. 
(D) shows many activated so called “foamy” macrophages in the active lesion centre. (E) delineates the rim of a chronic-
active lesion. The upper part still contains some blue-stained myelinated axons whereas the lower part of the picture is 
devoid of myelin. Characteristic for chronic-active lesions is the presence of activated microglia/macrophages at the lesion 
border (F). In contrast, microglia/macrophage numbers are low within the centre of the lesion (G).  
 
So called normal appearing white matter (NAWM) of MS patients is often used as control reference 
tissue, however some pathology is present in those areas as well [18, 19].  
Only little is known about demyelinating lesions in early MS. Lucchinetti and co-workers addressed 
this interesting issue by studying both autopsy and biopsy tissues from early RR-MS cases [20]. 
Despite the similarities in the inflammatory reaction (inflammatory infiltrates composed mainly of T 
cells and macrophages), the investigated lesions can be segregated into four distinct patterns with the 
common hallmark of myelin destruction. Pattern I lesions can be considered as sites of active 
demyelination associated with a T cell- and macrophage dominated inflammation. Pattern II lesions 
additionally display deposition of immunoglobulin and activated complement at sites of active myelin 
destruction. Both lesion types are typically centred by small veins or venules and show sharply 
demarcated edges. Loss of different myelin proteins, such as MAG, myelin oligodendrocyte protein 
                                                                               13 
(MOG), PLP, or 2',3'-cyclic nucleotide 3' phosphodiesterase (CNPase) occurs to the same extent. 
Pattern III lesions also contain an inflammatory infiltrate, composed mainly of T cells and 
macrophages/microglia, but there is no deposition of immunoglobulin or complement. Furthermore, 
lesions are not centred by veins but preservation of a rim of myelin is frequently observed around an 
inflamed vessel within the demyelinated plaque. Within pattern III lesions, myelin-forming 
oligodendrocytes show nuclear condensation and fragmentation which are typical signs of apoptosis. 
Pattern IV lesions contain microglia/macrophages and T cells (as pattern I lesions) but display 
significant cell death in the periplaque white matter. Pattern II is most frequently observed in MS 
cases, followed in the order of magnitude by pattern III, pattern I, and pattern IV. Interestingly, pattern 
III lesions were mainly found in patients with less than 2 months duration of disease before biopsy or 
autopsy [3].  
The concept of heterogeneity among lesions remains somewhat controversial. While different patterns 
of demyelination may exist early in the disease, this is probably not the case in patients with longer 
disease duration. In a recent study using an unselected pool of autopsy material from patients with a 
disease duration ranging from 7-51 years, lesion heterogeneity was not detected [21]. This study 
strongly suggests that, in contrast to early disease, there is a common mechanism of demyelination in 
established MS.  
 
1.7 Grey matter pathology in multiple sclerosis 
In MS, brain inflammation is associated with lesions appearing typically in plaques within the white 
matter (see fig. 1). Recent histopathological studies, however, convincingly show that grey matter 
regions, such as the forebrain cortex, are equally affected. Cortical demyelination can be widespread 
and was found to be most prominent in patients with either primary or secondary progressive MS, 
being rare or even absent in the acute or relapsing disease stage [22]. Cortical lesions can be classified 
in relation to their location. Lesions that extend across both white matter and grey matter are termed 
Type 1 lesions whereas lesions within the cerebral cortex that do not extend to the surface of the brain 
or to the subcortical white matter are classified as Type 2. The most common cortical lesion types are 
so called “subpial” Type 3 lesions. A common appearance of Type 3 lesions is that of long ribbons of 
subpial demyelination, often affecting several adjacent gyri. Type 4 lesions extend throughout the full 
width of the cerebral cortex, but do not reach into the subcortical white matter [23, 24].   
The pathology of grey matter lesions differs from that of white matter lesions in several aspects, such 
as  less pronounced lymphocyte infiltration, macrophage activity, complement composition or blood 
brain barrier alterations [21, 24-26]. The observed differences could be due to differences of the blood 
brain barrier or other elements of the cytoarchitecture of the cerebral cortex that make it more resistant 
to inflammation [25]. Given the extensive cortical involvement in patients with chronic MS, little T- 
and B cell infiltration in chronic cortical lesions, and extensive white matter demyelination in most 
MS patients, cortical MS lesions have been proposed to be degenerative in origin. However, whether 
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or not the development of cortical demyelinated lesions in MS displays a separate identity remains to 
be clarified.  
2. The toxic cuprizone demyelination model 
Cuprizone ingestion in mice induces a highly reproducible demyelination of certain brain regions, 
among them the corpus callosum (CC). This commissural white matter tract represents the most 
frequently investigated region in this animal model [3]. After 5–6 weeks (wks) of cuprizone treatment, 
the CC is almost completely demyelinated, a process called ‘‘acute demyelination’’. Acute 
demyelination is followed by spontaneous remyelination during subsequent weeks when mice are fed 
normal chow. In contrast, remyelination is highly impaired/delayed when cuprizone administration is 
prolonged (12-13 weeks or even longer), a process called ‘‘chronic demyelination’’. During late stages 
of acute demyelination, spontaneous remyelination occurs partially but fails under a continued 
cuprizone challenge [3].  
First experiments using cuprizone as a toxic compound date back to the late 1960s and were conducted 
by Carlton [27]. He reported that oxalic biscyclohexylidenehydrazide, a chelator used as a reagent for 
copper analysis, induces microscopic lesions in the brain accompanied by oedema, hydrocephalus, 
demyelination and astrogliosis. He administered different doses of cuprizone mixed in basic chow 
ranging from 0.2 to 0.5%. Mice fed cuprizone showed signs of growth retardation in a dose-dependent 
manner. At higher concentrations (0.5%), cuprizone caused high mortality especially when introduced 
in the chow early during development. The mortality in 4-week-old mice was 100%, whereas 
mortality declined to 20% in 8-week-old mice. In parallel, development of a severe hydrocephalus was 
more frequent in younger animals [28]. Based on these early findings, most laboratories use 6- to 9-
week-old mice feeding a diet containing 0.2–0.3% cuprizone. To assure proper demyelination in aged 
animals, the cuprizone concentration needs to be increased [29]. Furthermore, a strain-dependent 
susceptibility to cuprizone has to be considered. For example, it has been shown that SJL mice display 
a unique pattern of demyelination that does not follow the profile that is described in C57BL/6 mice. 
SJL mice do not readily demyelinate at the midline within the CC but show greater demyelination 
directly lateral to midline [30]. In our own studies, we continuously use C57BL/6 mice.  
As mentioned, cuprizone is a well-known copper-chelating agent, discovered and described in the 
early 1950s. The resulting copper–cuprizone complex is characterized by a very intense and unusual 
absorption band in the visible region, centred at 595 nm [31]. Due to the highly chromogenic reaction 
of cuprizone with copper (II) ions, cuprizone was largely exploited for the quantitative determination 
of copper in various samples. Starting from the early 1970s, a lot of interest focused again on 
cuprizone, mainly within the biomedical scientific community, as this compound was reported to 
possess unique neurotoxic properties and, therefore, to serve as a valuable pharmacological tool for 
CNS demyelination and spongiosis in various laboratory animals [3, 15]. The underlying mechanisms 
of cuprizone-induced oligodendrocyte cell death are not fully understood. It is well known that feeding 
of cuprizone causes the formation of mega-mitochondria in the liver. Liver tissue from cuprizone-fed 
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animals was studied with respect to mitochondrial dysfunction [32]. Since cuprizone induces 
alterations of mitochondrial morphology [3], it is speculated that the neurotoxic properties of this 
copper-chelating compound are due to a disturbance of cellular respiration, a key function of 
mitochondria. Since cuprizone-induced copper deficit might be detrimental to mitochondrial function 
in the brain [33] it has been assumed that it is a disturbance of energy metabolism in oligodendroglia 
and cell function that leads to demyelination [3, 15]. Why oligodendroglia should be preferentially 
susceptible to copper deficit is not known, although an obvious hypothesis is that the perikaryon of 
this cell type has to maintain a vast expanse of myelin and this extraordinary metabolic demand places 
it in jeopardy if the demand cannot be met. I will point out later that this assumption is probably not 
correct.  
3. Remyelination in multiple sclerosis 
Demyelination is still a characteristic entity for the pathology of MS but it has become increasingly 
apparent in recent years that substantial axonal and neuronal loss are equal important features [34-36]. 
Remyelination is the best-documented and most robust example of tissue repair in the human CNS and 
is unequivocally neuroprotective in MS. Approximately 40% of post-mortem MS tissues demonstrate 
remyelination which can occur early and late during the course of MS [37-39]. Remyelination 
represents one of the most effective mechanisms to achieve axonal protection in demyelinating 
disorders. Remyelination is believed to restore the structural integrity of the axon-myelin unit and 
axonal conduction properties that are lost following demyelination [40, 41]. It is unresolved why in 
some patients remyelination is widespread while in others, it is sparse. The increasing importance of 
axonal damage and loss as the pathological basis for progressive loss of function in MS demands a 
better understanding of the remyelination processes in MS and possible reasons for its failure. Several 
mechanisms have been suggested that may result in a blockade of remyelination. The loss and 
destruction of oligodendrocyte progenitor cells within the lesions in the course of repeated de- and 
remyelination might play an important role  [42, 43]. In some lesions, however, progenitor cells are 
abundantly present [44-47], but remyelination still fails either because axons are not permissive for 
remyelination [48] or the maturation of progenitor cells is inhibited [49].  
Cell types involved in endogenous remyelination might be local brain-resident cells such as astrocytes 
and microglia, or inflammatory cells from the peripheral vascular system such as leukocytes. Several 
factors have been described to be important for proper endogenous remyelination such as TNFα, 
interleukin 1β [50, 51] and hormones, i.e. oestradiol, progesterone and thyroxin [1, 52, 53]. On the 
other hand, recent studies identified additional factors which might contribute to remyelination failure 
such as the axon-derived polysialylated form of the neural cell adhesion molecule NCAM [48], 
LINGO-1 [54], myelin debris [55], or astroglial hyaluronan [56].  It is still not clear whether the lack 
of pro-myelinating factors or the presence of active remyelination inhibitors accounts for 
remyelination failure in MS lesions.  
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4. Aims and scope of the study 
Animal models are an irreplaceable tool for the development of new therapeutic strategies and options. 
A detailed understanding of MS pathology is of particular importance as is a detailed characterisation 
of the currently used animal models. Within my thesis, I characterized the toxic cuprizone model in 
detail. While many studies either investigate human or animal pathology and/or pathogenesis, 
translational research (i.e. a direct comparison of animal models with the disease presentation in 
humans) is necessary. One aim of my thesis was this essential step in MS research.  
Besides regional differences in cuprizone-induced demyelination, a better understanding of 
endogenous remyelination processes was a major objective of my studies. It is possible that the 
persistent expression of only one or two key inhibitors of remyelination (alternatively the restricted 
expression of inducers of remyelination) might act as ‘‘master regulators’’ of this process, thus 
preventing remyelination. However, it is more likely that non-remyelinating lesions result from an 
abnormal regulation of multiple steps during the remyelination process, resulting in a failure of the 
normal coordinated repair response after a demyelinating event. By using state of the art techniques 
(i.e. gene chip array analysis) we aimed to identify those factors and to investigate underlying 
mechanisms on the molecular level. Microglia cells as brain resident macrophages have been in the 
focus during demyelinating processes whereas the function of astroglia during tissue repair is 
highlighted in the remyelination phase. A better understanding of both cell populations will certainly 
broaden our knowledge of CNS disorders in general and, particularly, of MS.  
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Materials and Methods 
1. Animals and disease induction 
Mice (Charles River or Harlan Winkelmann, both Germany) were bred and maintained in a pathogen-
free environment. Animals underwent routine cage maintenance once a week and microbiological 
monitoring according to the Federation of European Laboratory Animal Science Associations 
recommendations. Food and water were available ad libitum. Research and animal care procedures 
were approved by the Review Board for the Care of Animal Subjects of the district government (North 
Rhine-Westphalia, Germany). Toxic demyelination was induced by feeding male C57BL6 mice (19-
21 g) a diet containing 0.2% cuprizone (Sigma-Aldrich, Germany) mixed into a ground standard 
rodent chow (Sniff, Germany) for 5 wks. The mixture was prepared fresh twice a week and stored at   
4 °C.  For experimental autoimmune encephalomyelitis (EAE) experiments, female SJL/J mice (6–8 
wks; 20 g body weight; Janvier, France) were immunized by subcutaneous injection of 250 µg of PLP 
peptide p139–151 (purity >95%; Pepceuticals, UK) in a 0.2 ml emulsion consisting of equal volumes 
of phosphate-buffered saline (PBS) and complete Freund’s adjuvant (CFA, Difco, USA) containing 6 
mg/ml Mycobacterium tuberculosis H37Ra (Difco, USA). Bordetella pertussis toxin (200 ng; List 
Biological Laboratories, Canada) was administered by intraperitoneal injection at days 0 and 2. Mice 
were scored as follows: 0, no disease; 1, tail weakness; 2, paraparesis; 3, paraplegia; 4, paraplegia with 
forelimb weakness; 5, moribund or dead.  
2. Tissue preparation  
For histological and immunohistochemical studies, mice were transcardially perfused with 2% 
paraformaldehyde containing saturated picric acid (pH 7.4). After overnight post-fixation in the same 
fixative, brains were dissected, embedded, and then coronary sectioned into 5 µm sections from the 
levels 205 to 275 according to the mouse brain atlas by Sidman et al. 
(http://www.hms.harvard.edu/research/brain/atlas.html). Spinal cord sections were prepared from the 
lumbar part. A detailed protocol for the transcardial fixation is given in Appendix 1. The protocol 
for paraffin-embedding is given in Appendix 2. For gene or protein expression analysis, mice were 
transcardially perfused with ice-cold PBS, brains quickly removed, and the entire corpus callosum and 
the adjacent cortex separately dissected using a stereo-microscopic approach. Tissues were 
immediately frozen in liquid nitrogen and kept at -80°C until used.  
3. Multiple sclerosis material 
Paraffin-embedded post-mortem CNS tissues were obtained through a rapid autopsy protocol from 
subjects with mostly progressive MS (in collaboration with the Netherlands brain bank Amsterdam). 
Biopsy tissue from patients diagnosed with inflammatory demyelination of the CNS consistent with 
MS was obtained from neurosurgery centres in Germany via the Department of Neuropathology in 
Göttingen, Germany. The biopsies were performed for diagnostic reasons, for example, to exclude 
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neoplastic- or infectious diseases and sent to the Department of Neuropathology in Göttingen for a 
second opinion. The study was approved by the institutional ethics review board and all donors or 
their relatives provided written consent for the use of brain tissues and clinical information for 
research purposes. Microscopic analysis of post-mortem samples was performed by two blinded 
readers (Prof. Sandra Amor and Prof. Paul van der Valk). Staging of lesions was performed as 
reported previously [17].  
For the study described in chapter 3, 167 tissue blocks from 21 post-mortem brains were included. The 
average age of patients was 66.48±13.0 (mean ± standard deviation). Average disease duration was 
31.35±13.2. Detailed clinical information is given in Appendix table 1. For the study described in 
chapter 4, six biopsies from 6 different patients and 25 tissue blocks from 7 post-mortem brains were 
included in the study. The average age of patients was 55.69±20.45. Detailed clinical information is 
given in Appendix table 2.  
4. Immunohistochemistry 
For IHC, paraffin-embedded sections were de-waxed, rehydrated, epitopes if necessary unmasked by 
either Tris/EDTA-buffer (pH 9.0) or citrate buffer (pH 6.0) and heating in a customary microwave, 
washed in PBS, quenched in H2O2, again washed in PBS and incubated overnight with the primary 
antibody diluted in blocking solution (Immunologic, Netherlands). Unspecific binding during mouse-
to-mouse protocols was minimized by incubating slides for 3h with blocking solution at room 
temperature (Immunologic, Netherlands). According to the manufacturer, the diluent contains complex 
proteins and non-protein mixtures which eliminate histostaining background by blocking Fc receptors 
and prevents non-specific protein-protein interactions. A complete list of antibodies used in the study, 
the applied concentrations as well as the performed heat-mediated antigen retrieval step is given in 
Appendix table 3. A detailed protocol for the entire IHC procedure is given in Appendix 3. For 
the visualisation of epitope-primary antibody complexes we used either the VECTASTAIN® ABC 
(peroxidase) system (vectorlabs, USA) or EnVision® polymer secondary antibodies (Dako, Germany). 
The VECTASTAIN® ABC-kit employs biotinylated secondary antibodies that form Avidin: 
Biotinylated enzyme complexes. This method has been termed the “ABC” technique [57]. The Dako 
EnVision® polymer system is a two-step IHC staining technique. This system is based on an 
horseradish peroxidise-labelled polymer which is conjugated with secondary antibodies. The labelled 
polymer does not contain avidin or biotin. Consequently, nonspecific staining resulting from 
endogenous avidin-biotin activity is eliminated or significantly reduced.  
5. Histochemistry 
Luxol Fast Blue and Periodic Acid Schiff (LFB/PAS) stainings were performed for the detection of 
myelin as published [58]. Sections were deparaffinized in a series of xylene (3 × 5 min) and partially 
dehydrated in 100% ethanol and 96% ethanol. Then, sections were incubated with 0.1% LFB (Gurr, 
UK) at 60°C for 3 h. After this, sections were rinsed in 96% ethanol for 10 s and subsequently rinsed 
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in distilled water. Sections were differentiated in 0.1% lithium carbonate and after this in 70% ethanol. 
Then, sections were rinsed in distilled water and incubated with 0.8% periodic acid solution for 
10 min. Thereafter, sections were rinsed in tap water and subsequently in distilled water. Sections 
were incubated with Schiff's solution (Merck, Germany) for 30 min. After a short rinse in tap water, 
sections were counterstained with haematoxylin for 5 min and intensely washed with tap water for 
5 min. 
6. Electron-microscopy and semi-thin sections 
For electron microscopy, mice were anesthetized and perfused with PBS followed by solution 
containing 4% paraformaldehyde and 2.5% glutaraldehyde. Brains were sliced into 1 mm sections, 
further trimmed and reoriented to obtain cross sections. Thin sections were cut and subsequently 
stained with uranyl acetate and lead citrate. Electron microscopy pictures were digitally recorded. This 
procedure was performed in collaboration with Prof. W. Baumgartner (RWTH-Aachen University, 
Department of Cellular Neurobionics). Technically, the entire procedure was performed by Agnes 
Weth. Evaluation of the pictures was performed by my self.  
7. Immunoflourescence double labelling 
For immunofluorescence double labelling, sections were rehydrated, unmasked by citrate buffer and 
heating, blocked with PBS containing 2% heat-inactivated fetal calf serum (FCS) (Gibco, Germany) 
and 1% bovine serum albumin (Sigma-Aldrich, Germany), and incubated for 90 min with the 
indicated combination of primary antibodies diluted in blocking solution. After washing, sections were 
incubated with a combination of fluorescent anti-mouse secondary antibodies (Alexa Fluor 488 
donkey IgG; Invitrogen, Germany) and fluorescent anti-rabbit secondary antibodies (Alexa Fluor 568 
goat IgG; Invitrogen, Germany) both diluted in blocking solution. Sections were then incubated with 
Hoechst 33342 (Invitrogen, Germany; 1:1000) diluted in PBS for the staining of cell nuclei. In order to 
exclude unspecific binding of the fluorescent secondary antibodies to primary antibodies, appropriate 
negative controls were performed by first incubating sections with the primary antibodies of murine 
origin and subsequently incubating these sections with fluorescent anti-rabbit secondary antibody and 
vice versa. Unspecific secondary antibody binding to the tissue itself was excluded by performing 
negative controls by incubating sections with each of the fluorescent secondary antibodies alone. 
Stained and processed sections were documented with the microscope working station Zeiss LSM 7 
Duo (Carl Zeiss AG, Germany). 
8. Scoring of demyelination and quantification of cell number 
In order to evaluate demyelination in PLP-stained sections of mice treated with cuprizone, we scored 
the CC between zero and three. A score of three is equivalent to the myelin status of a mouse not 
treated with cuprizone, whereas zero is equivalent to a totally demyelinated CC. A score of one or two 
corresponds to one-third or two-thirds fibre myelination of the CC, respectively. Loss of PLP 
immunoreactivity in PLP-induced EAE animals was quantified by measuring PLP-staining intensity 
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within the entire lumbar spinal cord using ImageJ (version 1.44h; Java 1.6.0_10). Results are 
expressed as percentage of entire spinal cord transverse section area. Loss of cortical PLP 
immunoreactivity in cuprizone-induced demyelination was quantified by measuring PLP-staining 
intensity within the region of interest (ROI) in binary-converted pictures using ImageJ (version 1.44h; 
Java 1.6.0_10). Results are expressed as percentage area of the entire ROI. A value of 100% represents 
a fully myelinated, 0% a fully demyelinated area. Quantification of astrocytes, oligodendrocytes, or 
microglia/macrophage numbers was done by manual counting the number of positive cells in the CC 
and lumbar spinal cord. Cell counting was performed using a Nikon Eclipse 55i (Nikon, Germany) 
and a 40x objective. Numbers are expressed as cells/mm2. 
9. Gene expression analysis  
Isolation of total RNA was performed with the NucleoSpin kit (Macherey-Nagel, Germany). RNA 
concentration and purity were assessed by using OD260 and OD260/OD280 ratio, respectively 
determined by the NanoDrop 2000 (Thermo Scientific, Germany). 1 µg RNA was subsequently 
reverse transcribed using an Invitrogen M-MLV RT-kit and random hexanucleotide primers 
(Invitrogen, Germany). Successful generation of cDNA was checked by conventional PCR using 
hypoxanthine guanine phosphoribosyl transferase 1 (HPRT) primers. HPRT, which plays a central role 
in the generation of purine nucleotides through the purine salvage pathway, is abundantly expressed in 
mammalian cells and thus can be regarded as a “housekeeping gene”. Housekeeping genes are 
typically required for the maintenance of basic cellular function, and are found in all cells of an 
organism. As illustrated in fig. 2, the applied mouse HPRT primer pair was designed as an intron/exon 
spanning oligonucleotide. The purpose of having primers that span at least one intron is to differentiate 
whether a band is amplified from genomic DNA or cDNA. If the isolated RNA is contaminated with 
genomic DNA and primers span one or more introns, one will get two bands with one from the cDNA 
and the other from genomic DNA. The “contaminated” genomic DNA band is longer, thus migrating 
slower during electrophoresis. In the given example, the specific cDNA amplicon should have a size 
of 248 base pair, the unspecific genomic DNA band of 1086 base pair, respectively.  Thus, successful 
reverse transcription as well as lack of genomic DNA contamination was checked by one single PCR.  
Thereafter, cDNA samples were diluted 1:10 in RNAse/DNAse free water (Invitrogen, Germany). 
Before diluting the cDNA, a certain amount of each cDNA sample was pooled and further diluted to 
create an internal standard curve. Reverse-transcription polymerase chain reactions (rtPCR) were 
carried out in a reaction mixture consisting of 2 µl diluted cDNA, 2 µl RNAse/DNAse free water, 5 µl 
SensiMixTM reagent (Bioline, Germany), and 0.5 µl of primer (10 pmol/µl; Invitrogen, Germany). 
Reactions were conducted in 96-well plate format using the MyIQ rtPCR Detection System (BioRad, 
Germany) under the following conditions: 10min enzyme activation at 95°C, 40 cycles of 15sec 
denaturation at 95°C, 30sec annealing at individual temperatures, 30sec amplification at 72°C, and 
5sec fluorescence measurement at 80°C. 
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Figure 2 
Organization of the HPRT1 mouse gene is illustrated. Exons are shown in brown characters. In between the exons, introns 
are shown in black characters. Green lines illustrate the positions of the forward and reverse oligonucleotide.  
 
 
Primer sequences are given in Appendix table 4. Relative quantification was performed by the 
∆Ct method, which results in ratios between target genes and a housekeeping reference gene (HPRT 
for mice tissue, 18s for human material). Because the validity of this method critically depends on the 
constant expression of the housekeeping gene, this prerequisite was tested for all treatment conditions. 
In each run, external standard curves were generated by several fold dilutions of target genes. The 
concentration of the target genes was calculated by comparing Ct values in each sample with Ct values 
of the internal standard curve. Finally, data were expressed as the ratio of the amount each transcript 
vs. the concentration of HPRT/18s. Melting curves and gel electrophoresis of the PCR products were 
routinely performed to determine the specificity of the PCR reaction. For each experiment, negative 
controls were performed in which 2 µl of RNAse/DNAse free water was added to the PCR reaction 
instead of cDNA. Positive controls using cDNA samples which were affirmed to contain the template 
to be amplified were performed as well.  
For end-point PCR, RNA isolation, purity assessment and reverse transcription were performed as 
described above. rtPCR reactions were carried out using a commercial PCR Kit (Bioline, Germany) 
and 2 µl undiluted cDNA and 0.25 µl of primer (10 pmol/µl; Invitrogen, Germany). Reactions were 
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conducted in standard tubes using the Mastercycler epgradientS (Eppendorf, Germany) under 
following conditions: 3 min of initial denaturation at 95°, followed by 35 cycles of each 40 s of 
denaturation at 95 °C, 45 s of annealing at individual temperatures and 40 s of elongation at 72 °C. 
Negative and positive controls were performed as already described above. After PCR reaction, cDNA 
samples were applied on a 2% agarose gel containing ethidium bromide and separated by 
electrophoresis (Bio-Rad, Germany). Pictures of gels were taken using the Alpha Imager 
(AlphaInnotech, USA).  
10. Affymetrix GeneChip® 
Regulation of gene expression in different treatment groups was analyzed by Affymetrix GeneChip® 
as published previously [59, 60]. Total RNA (n=3) was isolated and the quality assessed using RNA 
NanoChips with the Agilent 2100 Bioanalyzer (Agilent, USA). Probes for the GeneChip® Mouse 
Gene 1.0 ST Arrays (Affymetrix, USA) were prepared and hybridized to the arrays according to the 
Affymetrix GeneChip® Whole Transcript (WT) Sense Target labelling Assay Manual. Briefly, for 
each sample, 300 ng of total RNA was reverse transcribed into cDNA using a random hexamer 
oligonucleotide tagged with a T7 promoter sequence. After second strand synthesis the double-
stranded cDNA was used as the template for amplification with T7 RNA polymerase to create 
antisense cRNA. Random hexamers were then used to reverse transcribe the cRNA into single 
stranded sense strand cDNA. The sense cDNA was then fragmented by uracil DNA glycosylase 
(UDG) and apurinic/apyrimidic endonuclease 1. Fragment size was checked using a Bioanalyzer 
(Agilent, USA) with optimal fragment size in the 50-200 bp range. Fragmented sense cDNA was 
biotin-labelled with terminal deoxynucleotidyl transferase. The probes were then hybridized to the 
GeneChip® Human Mouse 1.0 ST Arrays at 45° C for 16 h, washed and stained on Fluidics Station 
450 and finally scanned on a GeneChip® Scanner 3000 7G (Affymetrix, USA). The image data were 
analyzed with AGCC (Affymetrix, USA). Gene expression levels were pre-processed with RMA 
algorithm [61]. Only those genes which were expressed higher than 3 fold over negative control in at 
least one treatment condition were further analyzed. Four different expression patterns (see below) 
were screened; 2 fold changes were used as cut-off for up/down regulation. Patterns were 
mathematically defined as follows: Econ, E5w, E13w are expression values in control, week 5, and week 
13 animals, respectively. Pattern 1: 2x Econ ≤ E5w ≥ E13w; Pattern 3: Econ ≥ 2x E5w ≤ E13w; Pattern 2: Econ 
= E5w ≥ 2x E13w; Pattern 4: Econ = E5w ≤ 0.5 x E13w. Genes following pattern 1 were further ranked 
according to magnitude of expression differences between expression values E5w and E13w. The 
following mathematical definition was applied (compare figure 2B):  2x Econ ≤ E5w ≥ E13w x Y, with 
Y=20/13 (30%); Y=20/14 (40%); Y=20/15 (50%); Y=20/16 (60%); Y=20/17 (70%); Y=20/18 (80%). 
Strictness of inclusion criteria increases with Y value. Genes in pattern 1 subgroup 50% (Y=20/15) 
were selected as candidate genes and analyzed for Gene Ontology enrichment with Bingo [62].  
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11. Transfection experiments 
U87 cells were transfected with either the empty pREP4 vector (controls) or a pREP4-BLBP 
expression construct as published previously [63]. Cultures were maintained in DMEM containing 10 
% FCS and antibiotics as published [64]. Selection of cultures was regularly performed in hygromycin 
(400 µg/mL, Invitrogen, Germany) for 48h. Transfected cells where kindly provided by our 
collaboration partner Prof. R. Godbout (University of Alberta, Department of Oncology, Edmonton, 
Canada).  
12. Western Blot analysis 
Protein isolation by homogenizing tissue samples in a RIPA lysis buffer composed of 150 mM NaCl, 
50 mM Tris (pH 8.0), 5 mM EDTA and 1% (vol/vol) Nonidet P40 was performed following standard 
protocols [29, 65]. Protease Inhibitor Cocktail Tablets supplied in a glass vial from Roche Applied 
Science, Germany were added to avoid protein degradation. After the isolation procedure, protein 
concentration measurement was performed using the bicinchoninic acid (BCA) protein assay kit 
(Thermo Scientific, Germany). This kit combines the well-known reduction of Cu2+ to Cu1+ by protein 
in an alkaline medium with the highly sensitive and selective colorimetric detection of the cuprous 
cation (Cu1+) by bicinchoninic acid. The BCA/copper complex was analyzed using a spectrometer at 
562nm wavelength (Tecan, Switzerland). Equal amounts of proteins were separated by 10% SDS-
PAGE, blotted onto nitrocellulose membranes (Amersham Hybond; GE Healthcare, Germany) and 
incubated with respective antibodies diluted in 5% milk TBS-Tween 0.01% over night (anti-GFAP, 
EnCor, USA). After washing and incubating with horseradish peroxidise conjugated anti-rabbit 
secondary antibody (goat IgG; Biorad, Germany), labelled proteins were visualized with ECL-reagent 
(GE Healthcare, Germany). After visualization, the antibodies were stripped from the nitrocellulose 
membrane by incubation with stripping buffer containing 50 mM Tris–HCl and 2% SDS at 70 °C for 
30 min. After washing the membrane, antibody incubation and visualization steps using anti-β-actin 
antibody (rabbit IgG; Sigma, USA) were performed as described above. 
13. Statistical analysis 
At least six animals were included for gene expression analysis by rt RT-PCR or IHC. Five animals 
were included for western blotting analysis. Differences between groups were statistically tested by 
ANOVA followed by a Tukey’s post-hoc multiple-range test using SPSS software (SPSS Inc., 
Chicago, IL, USA) except for differences between myelin scoring in cuprizone-treated animals. There, 
differences between groups were tested with the non-parametric Mann-Whitney-U-Test. All data are 
given as arithmetic means ± SEM. P values of the different analyses with p<0.05 were considered to 
be statistically different. 
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Results 
Chapter 1: The hippocampus and basal-ganglia complex are affected in the cuprizone 
model and multiple sclerosis 
 
There are several models available to study MS pathology. The most frequently used is the EAE 
rodent model. In this model, demyelinating foci are induced by immunization against a specific myelin 
antigen, although there is no evidence that human MS is triggered by a similar mechanism. A detailed 
histopathological study conducted by Lucchinetti et al. has highlighted the profound heterogeneity in 
the pattern of demyelination among MS patients [20]. One histopathological hallmark of MS is lesion 
dissemination in space. One focus of my thesis work concerns regional differences of MS pathology. 
Cuprizone-induced demyelination was believed to predominantly affect the CC and superior cerebellar 
peduncles. Consequently, the CC was in the focus of most of the studies [15]. We have now shown 
that cuprizone provokes additional demyelination in other brain areas such as the hippocampus [29], 
cerebellum [66], caudate putamen, and ventral part of the caudate nucleus [67]. Interestingly, distinct 
grey matter sub-regions in the cortex, within the hippocampus formation, and the striatal complex are 
also affected.  
In the following chapter, our most important findings are highlighted. Furthermore, I relate them to 
MS histopathology. As pointed out later, one important difference between white vs. grey matter 
pathology is the extend of microglia/macrophage activation.  
 
1.1 Cuprizone-treatment induces demyelination of the hippocampus 
Both, paraclinical and histopathological studies have shown that the hippocampus is affected in MS 
[68-70]. The hippocampus formation compromises one of the brain structures that seems to be crucial 
for long-term episodic memory performance, yet with a precise role that still remains elusive [71]. In 
line with the assumed hippocampal function in memory performance, a large number (40–65%) of 
patients with established MS experience cognitive deterioration of variable severity [72, 73]. Acute 
memory impairment has even been described as an initial distinct symptom in MS before the onset of 
well known and common sensomotoric impairment [74]. In the presented study, we have analyzed 
demyelination in distinct grey and white matter areas of the hippocampus in male mice [29]. The 
status of myelination and oligodendrocyte depletion was determined by histological staining and 
immunohistochemistry for proteolipoprotein (PLP). Ultrastructural changes were analyzed by electron 
microscopy. In addition, astrocyte and microglia responses were investigated in demyelinated 
hippocampus areas.  
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Figure 3 
Effects of cuprizone (5wks, 0.2%) on rodent hippocampus white and grey matter myelination, microgliosis and astrocytosis is 
demonstrated by anti-PLP, anti-Iba1 and anti-GFAP IHC, respectively. A (human) and B (mouse): Overview of the regions 
(anti-PLP staining) included in the study. (1) hilus of gyrus dentatus, (2-4) cornu ammonis subregions, (5) medial alveus and 
(6) fimbria. Regions outlined by boxes in (B) are shown in (C-N) in higher magnification. (C-H): Higher magnification views 
of the medial alveus. (I-N): Higher magnification views of the hilus region. (O): Ultrastructure of axonal demyelination in 
the cornu ammonis 2/3 (CA2/3) sub-region. Stars in (O) indicate a neuronal nucleus. Arrows in (O) indicate myelinated (left 
side) and demyelinated (right side) axons. Note that the demyelinated axon has a swollen morphology. Scale bars: 1000µm 
in (A), 350µm in (B), 20µm in (C-N), 2.5µm in (O). 
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Figs. 3A/B show an overview of the principal regions included in the study. Control human (fig. 3A) 
and mouse brains (fig. 3B) show differing myelin intensities throughout the hippocampus formation as 
assessed by anti-PLP IHC. Whereas high myelin content is present in the alveus (5) and fimbria (6), it 
is significantly lower in other areas, such as the gyrus dentatus (1) or cornu ammonis subregions (2-4). 
Thus, distinct myelin rich white matter regions as well as grey matter regions with sparse myelin 
content can be distinguished within the human and rodent hippocampus formation. The administration 
of cuprizone induced a highly reproducible demyelination of distinct hippocampal subregions (see 
figs. 3 C-N. White matter demyelination was mainly observed in the medial part of the alveus 
(compare figs. 3C vs. 3D) and the adjacent dorsal hippocampal commissure. The fimbria region and 
the lateral orientated alveus were just moderately affected (see chapter 2). In contrast, all hippocampal 
grey matter regions appeared to be equally affected by the administration of cuprizone (5wks 
cuprizone). Exemplarily, the hilar region of the gyrus dentatus with the adjacent granule cell layer is 
presented. Low PLP-immunoreactivity is present within that region in control animals (fig. 3I) 
whereas myelinated fibres are absent after 5 wks cuprizone exposure (fig. 3J). In parallel, there is a 
significant reduction in mature oligodendrocyte cell bodies, as demonstrated by anti-APC and anti-
Olig2 staining (data not shown) [29].  
To obtain information about cuprizone-induced ultrastructural changes in the mouse hippocampus, 
electron microscopy studies were performed on control mice and animals treated with cuprizone. 
Exemplarily, the stratum pyramidale of the cornu ammonis is presented (fig. 3O). Several axons with 
normal appearing myelin sheets (arrow) can be detected in the vicinity of neuronal cell bodies (star) in 
the cornu ammonis of control animals. As demonstrated, myelin sheets of most axonal fibres are 
destroyed by cuprizone application. Furthermore, axonal neurofilament networks appeared impaired, 
as shown in fig. 1O (arrow), indicating neurodegenerative processes besides demyelination. 
In summary,  
 
1.2 Inflammation is most pronounced in demyelinated hippocampal white matter structures 
Besides myelin and oligodendrocyte loss, we determined the brain-intrinsic inflammatory response i.e. 
astrocytosis and microgliosis within the affected white and grey matter of cuprizone-treated animals. 
IHC for Iba-1 to detect microglia/macrophages demonstrated a moderate, non-significant increase of 
microglia cell numbers in the affected grey matter (figs. 3K/L) after a 5 wks cuprizone challenge 
compared to controls. In contrast, a distinct increase in microglia cell number was clearly evident 
within the affected white matter area (figs. 3E/F). After 5 wks cuprizone exposure, higher numbers of 
GFAP-expressing astrocytes are seen within distinct hippocampal white (figs. 3G/H) and grey matter 
(figs. 3 M/N) sub-regions. In addition, the morphology of astrocytes revealed thin cells only 
possessing a few short processes under control conditions. In contrast, after cuprizone treatment, 
astrocytes became hypertrophic and multipolar. However, affected white matter areas clearly display 
more severe astrocytosis compared to the grey matter, respectively. In summary, our analysis revealed 
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that within the hippocampus formation, demyelinated white matter areas, such as the alveus or fimbria 
display a more severe inflammatory response compared to grey matter regions, respectively. 
 
 
Figure 4 
Human hippocampal white and grey matter demyelination and microgliosis is demonstrated by anti-PLP and anti-LN3 IHC, 
respectively. (A): Overview of a hippocampus mixed white and grey matter MS lesion (anti-PLP staining). Dotted line in (A) 
delineates the lesion, star the normal myelinated alveus, arrowheads the demyelinated part of the alveus, arrows the 
demyelinated cornu ammonis region. (B-E): Higher magnification views of the alveus. (F-I): Higher magnification views of 
the cornu ammonis region. Scale bars: 1000µm in (A) and 20µm in (B-I).     
 
 
1.3 Comparison of hippocampal lesions in the cuprizone model and multiple sclerosis 
As already reported by Geurts and colleagues [68], hippocampal lesions are a frequent phenomenon in 
MS. Lesions were either found solely within the hippocampus formation or involved both, 
hippocampal and para-hippocampal areas. We investigated the inflammatory response (i.e. microglia 
activation) within hippocampal white and grey matter regions of MS patients. Fig. 4A shows an MS 
plaque within the hippocampus formation (outlined by the dotted line). The star in fig. 4A marks the 
normal myelinated alveus region which is shown in fig. 4B in higher magnification. Within this 
normal appearing white matter part, just few LN3 (MHC class II)-expressing microglia/macrophages 
can be seen (fig. 4D). The demyelinated part of the alveus (marked in fig. 4A with arrowheads, shown 
in fig. 4C in higher magnification) contains several LN3+ cells (fig. 4E). Fig. 4F shows anti-PLP 
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staining of the normal appearing grey matter within the cornu ammonis region. Myelinated axons are 
present there. Those fibres can not be seen within the demyelinated part of the cornu ammonis grey 
matter (marked in fig. 4A with arrows, shown in fig. 4G in higher magnification). In contrast to the 
demyelinated white matter, the affected hippocampal grey matter does not show prominent foci of 
LN3-expressing microglia/macrophages (figs. 4H/I).  
 
 
Figure 5 
Human basal ganglia white and grey matter demyelination and microgliosis is demonstrated by anti-PLP and anti-LN3 IHC, 
respectively. (A): Overview of normal myelinated striatum (anti-PLP staining). Arrows indicate the white matter striosomes. 
(B): Striatal MS lesion (anti-PLP staining). (C-F): Higher magnification views of the striosomes. The original size of the 
striosome is delineated by the dotted line in (D). Arrows in (F) indicate LN3-expressing microglia/macrophages within the 
affected striosomes. (G-J): Higher magnification views of the grey matter matrix region. Scale bars: 800µm in (A/B) and 
20µm in (C-J). 
 
 
1.4 Basalganglia demyelination and inflammation 
Involvement of basal ganglia in MS appears to be related to a set of symptoms such as fatigue, 
impaired cognition, and movement disturbance.  We were recently able to show that the basal ganglia 
system is affected by cuprizone administration, as well [67]. White matter striosomes, located within 
the caudate-putamen and the ventral part of the caudate nucleus displayed intense demyelination, 
whereas those within the globus pallidus and the head of the caudate nucleus were not affected. The 
grey matter matrix region, however, was equally affected in the medial and lateral region. Besides 
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demyelination, we observed hypertrophic and hyperplastic astrocytosis and microglia cell 
invasion/local proliferation in the demyelinated areas.  
To compare histopathological changes between the cuprizone model and MS lesions, 19 basal ganglia 
lesions were analyzed for the expression of myelin proteins and microglia/macrophages. Exemplarily, 
the striatum as a part of the basal ganglia system is presented in fig. 5. As demonstrated, described 
changes in the basal ganglia system of cuprizone-treated animals closely reflect histopathological 
changes observed in the human situation. 8 out of 19 analyzed human basal ganglia lesions displayed a 
partial or complete preservation of myelinated axons within the striosomal compartment (figs. 5C/D). 
In contrast, the grey matter matrix region is almost completely demyelinated, as demonstrated by a 
definite loss of PLP-immunoreactivity (figs. 5G/H). Similar to our observations in the hippocampus, 
white matter areas display a more severe inflammatory response compared to grey matter regions 
within the basal-ganglia complex. In non-affected white matter striosomes, just some LN3-expressing 
microglia/macrophages are detectable (fig. 5E). In contrast, many activated microglia/macrophages are 
evident within the partially demyelinated striosomes (fig. 5F). Microgliosis is not evident in the 
demyelinated matrix region (figs. 5I/J).  
In summary we were able to show that feeding of cuprizone to young adult mice induces 
demyelination of different subcortical areas such as the hippocampus or the corpus striatum. 
Furthermore, we were able to demonstrate that within those regions, the brain-intrinsic inflammatory 
response (i.e. activation of microglia and astrocytes) is most severe in myelin rich areas. The same 
phenomenon was observed in respective regions of MS patients.  
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Chapter 2: Region-specific local brain responses account for regional differences in 
cuprizone-induced demyelination  
 
Parts of this work have been published in Inflamm Res. 2011 Aug;60(8):723-6. Epub 2011 Apr 24 
 
As pointed out above, regional differences can be observed in cuprizone-induced demyelination. Why 
some regions, such as the fimbria of the hippocampus, are resistant to the cuprizone challenge is not 
known. Interestingly, it has been shown by Hesse and colleagues that in early - but not in later - stages, 
dying oligodendrocytes express activated caspase 3, suggesting a switch from classical apoptotic 
pathways to caspase 3-independent mechanisms during the course of the cuprizone diet [75]. To 
understand more about selective regional vulnerability in this animal model we compared the 
cuprizone-resistant hippocampal fimbria with the cuprizone-vulnerable CC. We have focused on these 
two regions because both represent white matter areas, however, with a different vulnerability to the 
cuprizone challenge (see chapter 1 and Norkute et al. [29]). 
 
2.1 The hippocampal fimbria region is resistant to cuprizone intoxication despite microgliosis 
In a first set of experiments animals were fed cuprizone for 5 wks to induce acute demyelination of the 
CC. As already mentioned above, definite loss of PLP immunoreactivity can be observed in the CC 
(figs. 6B/E), whereas other regions appear unaffected such as the fimbria of the hippocampus (figs. 
6C/F). Both regions included in the subsequent study are indicated by the arrow and star in fig. 6D. 
Quantitative measurement of PLP staining intensity confirmed our observational results. There was a 
significant decrease in PLP staining intensity in the CC (control mean 69.2 ± 6.8 SEM vs. 5 wks 
cuprizone 19.4 ± 4.4; p<0.005). This was not observed in the fimbria (control mean 65.3 ± 5.1 SEM 
vs. 5 wks cuprizone 61.0.4 ± 3.2; p=0.49). To further investigate both regions on the cellular levels, 
we visualized microglia by anti-Iba1 and (activated) astrocytes by anti-GFAP antibodies, respectively. 
The quantification of fimbrial Iba1+ and GFAP+ cell numbers after acute cuprizone-induced 
demyelination is presented in figure 6U. Microglia were uniformly distributed in the CC (fig. 6G) and 
fimbria (fig. 6I) of control animals while a sustained increase in Iba1+ cell numbers was present in the 
demyelinated CC (fig. 6H) and, although to a lesser extend, in the fimbria (fig. 6J). After 5 weeks 
cuprizone, higher numbers of GFAP+ astrocytes were seen within the CC (fig. 6L) compared to 
controls (fig. 6K) but not in the fimbria (figs. 6M/N).  
 
2.2 Region specific inflammation determines demyelination in the cuprizone model 
Due to our observation that definite microgliosis can be observed within the white matter fimbria after 
acute cuprizone-induced demyelination, we assumed that the fimbria is affected as the CC by the toxin 
per se, but does not develop to a “classically” demyelinated lesion. To test for this hypothesis, animals 
were fed cuprizone in a second experiment up to 5 wks and sacrificed on day 2, week 1, week 2 and 
week 5 after start of the cuprizone diet. Cells with morphological characteristics typical for apoptosis 
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such as condensed and/or fragmented nuclei were seen at week 1 in both regions included in the study 
(figs. 6O/P). Control animals fed with powdered food without cuprizone were lacking apoptotic cells 
(data not shown). In a previous study, IHC for detection of CNPase confirmed that these apoptotic 
cells are oligodendrocytes [75].  
 
 
Figure 6 
Myelination and inflammatory cell composition in the medial corpus callosum (CC) and fimbria region of the hippocampus 
is presented. Anti-PLP antibodies were used to visualize intact myelin in sections of control and cuprizone treated animals 
(A-F). Anti-Iba1 and anti-GFAP antibodies were used to visualize microglia or astrocytes, respectively. Arrowhead in (D) 
indicates the medial part of the CC which is shown in (B/E, G/H, K/L and O) in higher magnification. The star in (D) 
indicates the fimbria region of the hippocampus which is shown in (C/F, I/J, M/N, P and Q-T) in higher magnification. 
Pictures (O/P) show H&E stained sections, illustrating apoptotic oligodendrocytes (arrows) within the CC and fimbria 
region. Quantification of Iba1+ microglia and GFAP+ astrocytes (fimbria region) in control and 5 weeks cuprizone treated 
animals is given in (U). Scale bars: 500µm (A/D); 50µm (B/C, E/F, G-N); 10µm (O/P); 8µm (Q-T); *p<0.05, **p<0.01, and 
***p<0.001.   
 
 
Anti-Iba-1 IHC revealed that pronounced microgliosis is evident in both regions after week 1. In 
control animals, Iba1+ cells displayed a typical ramified morphology indicating a resting state (fig. 
6Q). At week 1 (fig. 6S), and week 2 (fig. 6T) processes of microglia cells within the fimbria appeared 
to be retracted and cell bodies were swollen which is frequently associated with microglia activation 
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[76]. Comparable morphological changes of microglia were evident in the CC at week 1 and 2. While 
the magnitude of microgliosis progressed in the CC until week 5 (fig. 6H), a reduction of microglia 
cell numbers could be observed in the fimbria. Only a moderate activation of fimbrial astrocytes was 
detectable at week 2 (increased number and swollen processes), whereas at all other time points 
included in the study, astrocytic cell parameters were the same as observed in the fimbria of control 
animals. Within the CC, astrocytosis started at week 2, however, in contrast to the fimbria progressed 
in the CC until week 5.  
It might be feasible that regional differences exist in microglia function as previously suggested [77]. 
We assume that some intrinsic signalling contributes to a “switch” from an anti-inflammatory to a pro-
inflammatory phenotype of microglia within the affected CC. The first phenotype is also called “M2 
or alternatively activated”, the later one “M1 or classically activated” [78, 79]. Therapeutic bolstering 
of this apparent regulation could, therefore, be effective in halting the formation of new destructive 
lesions in MS.  
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Chapter 3: Inflammatory response depends on extend of myelin loss in experimental 
demyelination and multiple sclerosis Type 1 lesions 
 
Our results from chapter 2 strongly suggest that brain-intrinsic inflammation, among others 
microgliosis, is critical for MS lesion progression. In MS, the pathology of grey matter lesions differs 
from that of white matter lesions in several aspects, such as  less pronounced lymphocyte infiltration, 
complement composition, blood brain barrier alterations or microglia/macrophage activity [21, 24-26]. 
The observed differences could be due to differences of the blood brain barrier per se or other 
elements of the cytoarchitecture of the cerebral cortex that make it more resistant to inflammation 
[25]. However, the reduced inflammatory response in grey matter lesions, especially 
microglia/macrophage activation, could simply be due to the lower grey matter myelin content and in 
consequence less myelin debris during a demyelinating event. In the present study we used the toxic 
cuprizone demyelination model [3] to study the relation between myelin debris and 
microgliosis/astrocytosis in the demyelinated forebrain white and grey matter. Our findings were 
opposed to human pathology.   
 
3.1 Cortical grey matter demyelination is prominent in the cuprizone model 
It has been recently reported that cortical demyelination is a prominent feature in the murine cuprizone 
model [80]. In a first set of experiments we reassessed extend and pattern of cortical demyelination 
after acute cuprizone-induced demyelination (5 wks). Fig. 7A shows a frontal sectioned mouse brain 
slice at the level of bregma zero indicating the two principal regions included in the study, i.e. the 
primary somato-motor (pMcx) and somato-sensory (pScx) area, respectively. Both cortical layers each 
contain a characteristic distribution of neuronal cell types and can thus be distinguished. The pMcx 
consists of five layers (termed agranular cortex) whereas the pScx of six layers (termed granular 
layer), respectively. A representative overview of PLP-stained control and cuprizone-treated brains is 
shown in figs. 7B/C. Figs. 7D/E show the pMcx and pScx of control animals in a higher 
magnification, whereas figs. 7F/G show respective regions of cuprizone-fed animals. As illustrated, 
cuprizone exposure resulted in a massive demyelination as detected by a loss of PLP-stained fibres in 
all cortex regions compared to controls. In control animals, myelinated axons are densely packed 
within the large areas of the cortex sparing the molecular layer 1. After 5 wks cuprizone treatment, 
many PLP+ fibres can be detected within layer 6 of the pMcx, whereas layers 1 to 3 are almost 
completely demyelinated. The pScx displays a similar demyelination pattern however, some PLP+ 
fibres are visible within layer 4 (arrows in fig. 7C).  
 
3.2 Magnitude of myelin loss within the cortical grey matter of cuprizone-treated mice 
Since the different cortical layers can be easily identified within the granular pScx compared to the 
agranular pMcx with rather blurry borders between the different layers, we were intended to quantify 
changes in PLP immunoreactivity within the pScx region (see fig. 8).  
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Figure 7 
Effect of cuprizone (5wks, 0.2%) on rodent cortical grey matter myelination is presented by anti-PLP IHC. (A): Nissl-stained 
overview of the principal regions included in the study, i.e. the primary somato-motor (pMcx) and somato-sensory (pScx) 
area. (B/C): Overview of anti-PLP stained mouse sections of a control and cuprizone treated animal, respectively. Dashed 
lines in (B) delineate the different cortical layers 1-6. Arrows in (C) mark the internal granular layer 4. Note that PLP-
immunoreactivity can be detected in cortical layers 4 and 6 after 5 wks cuprizone treatment. (D/E): Higher magnification 
views of respective cortical regions in control animals. (F/G): Higher magnification views of respective cortical regions after 
5 wks cuprizone treatment (all anti-PLP staining). Scale bars: 350 µm (B/C); 50 µm (D-G).  
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Evaluation was separately performed for layer1, layers 2/3, layer 4 and layer 6. Quantification of PLP 
staining intensity revealed a reduction in all pScx layers included in the analysis. Due to low PLP 
levels in superficial cortical layers under control conditions with a gradual increase towards layer 6 
(compare fig. 8A), extend of cortical myelin loss was greatest in layer 6 and lowest in layer 1. 
To compare extend of myelin loss in the myelin-rich layer 6 with the white matter, the CC was 
included in the analysis. As demonstrated in fig. 8A, PLP staining intensity in layer 6 was ~50% 
compared to the myelinated CC (midline) in control animals. After 5 wks cuprizone exposure, PLP 
staining intensity was comparable in both regions. Thus, extend of myelin loss in layer 6 is still lower 
compared to the affected CC. We further performed semi-quantitative gene expression of PLP (fig. 
8B) and MBP (fig. 8C) mRNAs as markers for myelinating oligodendrocytes in entire cortex samples. 
As shown, both oligodendrocyte marker mRNAs were already decreased after one week and remained 
at this low level. Reduction in PLP mRNA transcript levels was more pronounced (5% at week 1 
compared to controls; p<0.001) compared to the reduction in MBP mRNA levels (47% at week 2 
compared to controls; p<0.05).  
 
3.3 Demyelination is paralleled by oligodendrocyte loss 
We next quantified the number of Olig2+ oligodendrocytes in different pScx layers. Under control 
conditions, oligodendrocyte numbers gradually increase from layer 1 towards layer 6. As shown in fig. 
8D, a reduction of oligodendrocyte cell number could be observed in all layers after 5 wks cuprizone 
exposure. In layer 1, mean numbers of Olig2-expressing cells declined from 154±17 cells/mm2 
(control) to 119±11 (5wks; not significant), in layers 2/3 from 199±18 to 134±8, in layer 4 from 
401±29 to 103±12, and in layer 6 from 773±40 to 211±29, respectively.  
Furthermore, numbers of Olig2+ cells in perineuronal and non-perineuronal position (i.e. satellite and 
myelinating oligodendrocytes, respectively) were quantified in layer 6. As shown in fig. 8E, numbers 
of satellite (illustrated in fig. 8F) as well as myelinating cortical oligodendrocytes significantly 
decreased during a 5 wks cuprizone treatment period. Remarkably, percentage decline of either Olig2+ 
cell population was comparable (-75% for satellite and -73% for myelinating oligodendrocytes, 
respectively).  
 
3.4 Microglia and astrocyte response are mainly determined by myelin debris 
As already pointed out above, astrocytosis and microglia cell invasion and/or proliferation are well-
known phenomena during cuprizone-induced demyelination [12, 29, 52, 66, 81]. To asses whether the 
activation of both cell types depends on the extend of myelin loss, number of GFAP+ astrocytes and 
Iba1+ microglia were quantified in cortical layers 1 (low extend of demyelination), 4 (intermediate 
extend of demyelination), and 6 (high extend of demyelination). As shown in figs. 9A/B, IHC for Iba1 
to detect microglia/macrophages demonstrated that microglia is uniformly distributed in the pScx in 
control animals. During cuprizone-induced demyelination, pronounced accumulation of microglia 
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cells was observed. Microglia accumulation was most severe within the multiform layer 6 next to the 
demyelinated CC after 5 wks cuprizone treatment (4th column in fig. 9B). A moderate increase in 
microglia numbers was evident in layer 4 whereas no increase was evident in layer 1 (2nd and 3rd 
columns in fig. 9B, respectively). Extend of microgliosis was most pronounced in the CC (5th row in 
fig. 9B). 
 
 
 
Figure 8 
Effect of cuprizone (up to 5wks, 0.2%) on cortical myelination (anti-PLP staining), myelin-related transcript levels (PLP and 
MBP mRNA), oligodendrocyte cell numbers (anti-Olig2) and perineuronal vs. satellite oligodendrocytes is presented. (A): 
Densitometric quantification of PLP-staining intensity in different primary somato-sensory areas (pScx) and the corpus 
callosum (CC). (B/C): PCR expression analysis of PLP and MBP within the entire cortex, respectively. Each bar represents 
the averaged fold reduction over untreated control mice of at least six mice per time point (±SEM). Values were normalized 
against a housekeeping gene (HPRT) and expressed as % of controls. (D): Results of Olig2+ cell number quantification in 
different primary somato-sensory areas. (E): Results of perineuronal (PN) satellite and myelinating (MOL) oligodendrocyte 
quantification in layer 6 of the primary somato-sensory cortex of control animals and animals treated 5wks cuprizone. Two 
satellite oligodendrocytes are illustrated in (F) where oligodendrocytes are visualized by anti-Olig2 staining. Arrows in (F) 
mark HE-stained neuronal nuclei. Scale bar: 30 µm (F); *p<0.05, **p<0.01, and ***p<0.001. 
 
 
To study the time course of microglia activation within the entire telencephalic cortex, CD11b 
expression analysis was performed after 1, 2, 3 and 5 wks cuprizone treatment and compared to 
control animals. As shown in fig. 9C, quantification of CD11b mRNA expression in the total cortex 
without the adjacent CC supports the above observation. CD11b mRNAs were significantly increased 
after one week of cuprizone exposure (234% compared to controls, p<0.001). Expression remained 
stable till week 5.  
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Figure 9 
Effect of cuprizone (up to 5wks, 0.2%) on cortical microgliosis (anti-Iba1 staining) is presented.  (A): Results of Iba1+ cell 
number quantification in different primary somato-sensory areas. (B): Representative anti-Iba1 stained mouse sections of 
respective primary somato-sensory cortical layers and the corpus callosum (CC). The upper row in (B) shows representative 
pictures of control animals whereas the lower row shows representative pictures of animals treated 5wks cuprizone. The 1st 
column in (B) shows an overview of the entire primary somato-sensory area. Respective layers are presented in columns 2-4 
in higher magnification. Anti-Iba1 stained corpus callosum sections are presented in the 5th column. Star in the 1st column 
indicates microglia-rich layer 6 after cuprizone treatment. Note that microglia cells have several processes in the cortex 
whereas they are amoeboid-shaped in the affected corpus callosum after 5 wks cuprizone-induced demyelination. Real-time 
RT-PCR expression analysis for CD11b of the entire cortex is presented in (C). Each bar represents the averaged fold 
induction over untreated control mice of at least six mice per time point (±SEM). Values were normalized against a 
housekeeping gene (HPRT) and expressed as % of controls. Scale bars: 50 µm (B, 1st column); 20 µm (B, other columns); 
*p<0.05, **p<0.01, and ***p<0.001.   
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Under control conditions, only few GFAP+ cells were present. Within layer 1, GFAP+ cells were 
regularly detectable within the subpial compartment and build up the glial limiting membrane 
(arrowheads in fig. 10B). Within layers 2-5, GFAP-expressing cells were usually found around blood 
vessels (arrow in fig. 10B). Rarely, GFAP+ cells can be found within cortical layers 2-5 apart from 
blood vessels. In contrast, several GFAP-expressing astrocytes are visible in layer 6 next to the CC 
(star in fig. 10B). The morphological appearance of astrocytes revealed thin cells with few short 
processes under control conditions. After cuprizone treatment, astrocytes become hypertrophic and 
multipolar. As demonstrated in figs. 10A/B, number of GFAP+ cells increased in all layers. However, 
astrocyte hypertrophy displayed striking regional differences. Superficial layers displayed moderate 
astrocyte hypertrophy (2nd row in fig. 10B), whereas most severe astrocyte hypertrophy was evident at 
the border of layer 6 to the white matter tract CC (4th row in fig. 10B). Moderate astrocyte hypertrophy 
was evident in layer 4 (3rd row in fig. 10B). Extend of astrocytosis (both increase in cell numbers and 
cell size) was most pronounced in the CC (5th row in fig. 10B). To study the time course of astrocyte 
activation within the entire telencephalic cortex, GFAP expression analysis was performed after 1, 2, 3 
and 5 wks cuprizone treatment and compared to control animals. As shown in fig. 10C, quantification 
of GFAP mRNA expression in the total cortex without the adjacent CC supports the above 
observation. GFAP mRNAs were significantly increased after two wks of cuprizone exposure (471% 
compared to controls, p<0.001). Expression gradually increased till week 5 (612%).  
 
3.5 Magnitude of microglia activation in Type 1 multiple sclerosis lesions depends on lesion activity  
The results from the cuprizone model implicate that extend of microgliosis depends on the amount of 
myelin loss and, thus, on myelin debris present in the lesion. Whether the same holds true for MS is, 
however, not easy to investigate. While white matter lesions can clearly be classified to be active or 
inactive, most grey matter lesions lack microglia activation making them somehow difficult to stage. 
Thus, the lack of activated microglia cells in a given grey matter lesion might be because the lesion is 
already inactive (in other words old) or grey matter lesions do not display microgliosis per se. It 
appears obvious that mixed white-grey matter Type 1 lesions develop at the same time. Thus, the 
lesion stage of Type 1 lesions can be determined in the respective white matter part of the lesion. 
Following this attractive strategy, we determined the inflammatory infiltrate in different Type 1 
lesions separately for the white and grey matter part. This enables us to analyze the inflammatory 
infiltrate within the myelin rich white matter and the myelin poor grey matter part. Furthermore, we 
included the visual cortex in our analysis. This region contains a myelin rich island, the so called 
“Gennari stripe”. If our hypothesis that myelin debris is the major predictor for microgliosis is correct, 
one would expect more pronounced microglia activation within the demyelinated Gennari stripe 
compared to the surrounding sparse-myelinated grey matter areas.  
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Figure 10 
Effect of cuprizone (up to 5wks, 0.2%) on cortical astrocytosis (anti-GFAP staining) is presented.  (A): Results of GFAP+ cell 
number quantification in different primary somato-sensory areas. (B): Representative anti-GFAP stained mouse sections of 
respective primary somato-sensory cortical layers and the corpus callosum (CC). The upper row in (B) shows control 
animals whereas the lower row animals treated 5wks cuprizone. The 1st column in (B) shows an overview of the entire 
primary somato-sensory area. Respective layers are presented in columns 2-4 in higher magnification. Anti-GFAP stained 
corpus callosum sections are presented in the 5th column. Star in the 1st column indicates the white-grey matter junction 
whereas arrowhead indicates the glia limitans. Note the pronounced increase in cell number (hyperplasia) and cell volume 
(hypertrophy) especially in layer 6 and the corpus callosum after 5 wks cuprizone exposure. Real-time RT-PCR expression 
analysis for GFAP of the entire cortex is presented in (C). Each bar represents the averaged fold induction over untreated 
control mice of at least six mice per time point (±SEM). Values were normalized against a housekeeping gene (HPRT) and 
expressed as % of controls. Scale bars: 50 µm (B, 1st column); 20 µm (B, other columns); *p<0.05, **p<0.01, and 
***p<0.001.   
 
 
We screened paraffin-embedded post-mortem CNS tissues for the presence of cortical Type 1 lesions. 
From the 167 tissue blocks, we identified and analyzed 26 blocks from 9 MS brains, which contained 
Type 1 lesions. 13 blocks contained chronic-active, 8 chronic-inactive and 5 active Type 1 lesions. 
One representative chronic active Type 1 grey matter lesion is shown in fig. 11. As indicated in figs. 
11B-D, both parts of the lesion display an almost complete loss of PLP staining intensity. Within the 
white and grey matter part of (chronic)-active Type 1 lesions, the difference in morphology of LN3+ 
cells was striking. Within the cortical part, most cells projected processes and retained the morphology 
of activated microglia (see arrow in fig. 11G). In contrast, regularly amoeboid-shaped LN3+ cells were 
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present in the white matter part (see arrowheads in fig. 11F). Quantification of microglia/macrophages 
in different Type 1 lesions is presented in fig. 11A. As expected, LN3+ cell numbers were significantly 
higher in (chronic)-active white matter lesions compared to (i) NAWM or (ii) chronic inactive white 
matter lesions (black columns). As demonstrated in fig. 11A, number of LN3-expressing cells was 
significantly higher in (chronic)-active grey matter lesions compared to (i) NAGM or (ii) chronic 
inactive grey matter lesions (grey columns). The (chronic)-active grey matter parts contained ~ five 
times fewer LN3+ cells compared to the respective white matter parts.  
To further elaborate extend of LN3+ cell accumulation in the demyelinated cortex as a function of 
myelin loss, tissue blocks were screened for visual cortex lesions. This region contains a myelin rich 
cortical layer, i.e. the line of Gennari (layer 4). As shown in figs. 11H-M, the inflammatory infiltrate 
was found to be more pronounced in the demyelinated myelin rich cortical layer 4 compared to the 
other affected layers. Within the line of Gennari, LN3-expressing cells were found to be swollen and 
have just few, short and thick processes. In contrast, LN3+ cells display a more ramified morphology 
in the other demyelinated layers (compare figs. 11J/M).    
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Figure 11 
Myelination and microglia/macrophage response in mixed white-grey matter Type 1 and transcortical Type 4 MS lesions is 
presented by anti-PLP and anti-LN3 (MHC class-II) IHC, respectively. (A): Results of MHC class II (LN3)+ cell number 
quantification in grey and white matter parts of different Type 1 cortical lesions (active, chronic active, inactive), normal 
appearing white matter (NAWM) and normal appearing grey matter (NAGM). (B/E): Overview of a representative anti-PLP 
(B) or anti-LN3 (E) stained chronic-active Type 1 lesion. As indicated in (B), the lower part represents the demyelinated 
white matter part (WML), the upper part the demyelinated grey matter part (GML), respectively. (C/D and F/G): Higher 
magnification view at the lesion rim of anti-PLP and anti-LN3 stained sections, respectively. Arrowheads in (F) indicate 
amoeboid shaped macrophages. Arrow in (G) indicates a microglia cell with several thin processes. (H-M): Type 4 grey 
matter lesion of the primary visual cortex (anti-PLP and anti-LN3 IHC, respectively). Arrowheads in (H) indicate the myelin-
rich Gennari stripe (layer 4) within the normal appearing grey matter. The upper box in (K) marks demyelinated grey matter 
in myelin-poor layers 1-2, shown in (I/J) in higher magnification. The lower box in (K) marks demyelinated grey matter in 
the myelin-rich Gennarri stripe, shown in (L/M) in higher magnification. Note that macrophages within the affected myelin-
rich Gennari stripe are amoeboid whereas they are lank with several thin processes in affected myelin-poor superficial 
cortical layer. Scale bars: 800 µm (B/E/H/K); 20 µm (C/D/F/G/I/L), 10 µm (J/M); *p<0.05, **p<0.01, and ***p<0.001.   
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Chapter 4: Brain lipid binding protein expression in activated astrocytes: potential 
target for remyelination therapy 
 
Parts of this work have been published in Brain Behav Immun. 2011 May 1 
 
Remyelination represents one of the most effective mechanisms to achieve axonal protection in 
demyelinating disorders. Remyelination is believed to restore the structural integrity of the axon-
myelin unit and axonal conduction properties that are lost following demyelination [41, 82]. It is 
unresolved why in some patients remyelination is widespread while in others, it is sparse. The 
increasing importance of axonal damage and loss as the pathological basis for progressive loss of 
function in MS demands a better understanding of the remyelination processes in MS and possible 
reasons for its failure. Several mechanisms have been suggested that may result in a blockade of 
remyelination. The loss and destruction of oligodendrocyte progenitor cells within the lesions in the 
course of repeated de- and remyelination might play an important role [83]. In some lesions, however, 
progenitor cells are present [44-47], but remyelination still fails either because axons are not 
permissive for remyelination [48] or the maturation of progenitor cells is inhibited [49].  
Glial cells, and particularly astrocytes, were found to be highly abnormal early in the course of MS. 
They undergo several morphological and biochemical changes referred to as reactive astrogliosis. The 
hallmarks of astrogliosis are hypertrophy of cellular processes, up-regulation of GFAP and vimentin, 
and re-expression of developmentally-related proteins such as nestin [84]. Astrogliosis varies 
quantitatively and qualitatively depending on the nature of injury and its micro-environment. It is 
likely that reactive astrocytes represent a heterogeneous population [59]. Consequently, activated 
astrocytes have been described as either beneficial or detrimental in CNS recovery after injury [84]. 
Factors responsible for the biochemical heterogeneity of reactive astrocytes are not known and nor are 
their different functions in vivo well understood. Regional differences in astrocytes, their activation 
state and the timing after injury may determine their function and their capability to aid or inhibit 
remyelination. Benefit may be gained from reactive astrocytes during early demyelination events, 
whereas later after demyelination, the net effect may be inhibitory for remyelination.  
The cuprizone model is well-suited to study brain intrinsic events during demyelination and 
remyelination [3]. In this animal model, extensive remyelination is evident after acute demyelination 
whereas remyelination is impaired after prolonged cuprizone exposure.  
Brain lipid binding protein (BLBP) belongs to the family of fatty acid-binding proteins (FABPs). 
FABPs are cytoplasmic 14-15 kDa proteins which are supposed to be involved in fatty acid uptake, 
transport, and targeting. Ten FABP genes have been identified showing a specific tissue distribution 
[85]. Brain FABP, also called FABP7 or BLBP, is widely used as a radial glia cell marker [5, 86-88] 
and expressed in cells of the astrocyte lineage [63, 89].  
The aim of this study was to elucidate differences in brain intrinsic gene expression during an early 
and late demyelinating event and to relate gene expression profiles to remyelination and its failure. To 
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this end, we performed Affymetrix GeneChip® analysis from RNA of dissected CC after acute (5 
wks) and chronic (13 wks) cuprizone-induced demyelination. Our findings clearly show a correlation 
between inflammatory gene transcripts and remyelination. Furthermore, BLBP expression by activated 
astrocytes is highly up-regulated during early disease courses but declines as disease progresses. 
Expression of BLBP in activated astrocytes was further corroborated in the EAE model and early vs. 
late human MS disease stages. The number of BLBP-expressing astrocytes declines with MS disease 
duration. In vitro studies demonstrated that the induced expression of BLBP in BLBP-negative human 
malignant glioma cell lines (U87) enhances the expression of fibroblast growth factor 2 (FGF2), 
platelet-derived growth factor alpha polypeptide (PDGF-AA), and osteopontin (SPP1).   
 
4.1 Remyelination is limited after prolonged cuprizone exposure despite the presence of 
oligodendrocyte progenitor cells 
We first reassessed the remyelination capacity of brains after acute and chronic cuprizone-induced 
demyelination. Remyelination capacity was tested after a 4-wk remyelination period after acute (5 wk) 
and chronic (13 wk) cuprizone-induced demyelination. Under these conditions, the CC is severely 
demyelinated after 5 and 13 wks of cuprizone treatment as demonstrated by anti-PLP IHC (figs. 12A-
C; medial part of CC shown in higher magnification in figs. 12D-F). The myelin status of the CC 
significantly improves after acute demyelination during a 4 wk follow-up period as demonstrated by 
definite recovery of PLP immunoreactivity. In contrast, endogenous remyelination almost completely 
fails after chronic cuprizone exposure (figs. 12G/H). Within the acutely and chronically demyelinated 
lesions APC-positive oligodendrocytes can be found (figs. 12I/J). Additionally, we quantified 
Olig2strong+ oligodendrocyte progenitor cell (OPC) numbers (figs. 12K/L). No significant difference 
was observed between the acutely and chronically demyelinated CC. Mean numbers were 345 ± 42.7 
after acute vs. 427 ± 8 after chronic demyelination with p = 0.21. These findings clearly demonstrate 
that in the chronically demyelinated CC, remyelination is highly impaired despite the presence of pre-
mature oligodendrocytes.   
 
4.2 Remyelination appears to be limited due to the absence of pro-myelination factors 
To identify genes which are differentially regulated after acute and chronic demyelination and, 
therefore, might be involved in endogenous remyelination, we used Affymetrix GeneChip® arrays as 
previously published [60]. Two different analytical approaches were performed. The first approach 
assumes that potential pro-myelination factors display an abundant expression after acute 
demyelination, whereas expression of these factors is reduced, when remyelination fails (fig. 13A, 
pattern I). 
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Figure 12 
Remyelination capacity after cuprizone-induced acute (5 wks) and chronic (13 wks) demyelination is presented. (A-H): 
Myelination of the midline of corpus callosum after different cuprizone treatment periods (anti-PLP IHC). In control 
animals, the medial (arrowhead in A) and lateral (arrow in B) part of the corpus callosum are well myelinated. (B/C) show 
by an overview that both parts of the corpus callosum are severely demyelinated after 5 and 13 wks cuprizone treatment. (D-
H): Higher magnification views (anti-PLP IHC). Note that significant remyelination occurs after acute demyelination (G), 
indicated by recovery of PLP immunoreactivity within the medial part of the corpus callosum whereas this region is almost 
devoid of any PLP+ fibres in the chronically demyelinated group (H). (I/J): Visualization of late-stage oligodendrocytes 
(anti-APC IHC). Note that both lesions contain several APC+ oligodendrocytes. However, oligodendrocytes display a 
shrunken morphology in the chronically but not acutely demyelinated corpus callosum. (K/L): Visualization of 
oligodendrocyte progenitor cells (anti-Olig2 IHC). Note the presence of olig2strong+ oligodendrocyte progenitor cells after 
acute and chronic demyelination. Scale bars: 1 mm (A-C); 30 µm (D-H); 10 µm (I-L).  
 
 
The second approach assumes that potential anti-myelination factors display an expression down-
regulation after acute demyelination, whereas suppression of these factors is not present in the 
chronically demyelinated brain (fig. 13A, pattern II). Evaluation of Affymetrix GeneChip® analysis 
revealed that many genes followed pattern I whereas far less genes followed pattern II. The number of 
genes following pattern I depending on the strictness of criteria applied is presented in fig. 13C 
(strictness increases with y value, see fig. 13B). Eight genes followed pattern I with y = 0.8, 20 genes 
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with y = 0.7, 44 genes with y = 0.6, 74 genes with y = 0.5, 118 genes with y = 0.4, and 168 genes with 
y = 0.3, respectively. For y = 0.5, just 5 genes followed pattern II (see table 1).  
 
 
Figure 13 
Applied strategy for gene-array evaluation is presented. (A): Anticipated expression patterns of pro-myelinating and anti-
myelinating factors. (B): Mathematical formula used as inclusion criteria depending on the strictness of the applied criteria. 
(C): Number of genes following pattern I depending on strictness of inclusion criteria applied. Note that strictness of 
inclusion criteria increases with y value. Hatched column in (C) indicates that 74 genes follow pattern I for y = 0.5 which are 
listed in table 3. 
 
 
4.3 Inflammatory response is critical for endogenous remyelination 
Genes detected to follow pattern I (for y = 0.5, see hatched column in fig. 13C) were grossly 
categorized according to their biological function given by the Gene Ontology database 
(http://www.geneontology.org). One should note that the relatively strict standards applied (see 
materials and methods section) are likely to generate false-negative signals but less likely to produce 
false-positive signals. The most impressive finding is the predominance of immune and stress-
response factors of genes following pattern I (see table 1). Many of the discovered genes are related to 
microglia/macrophages activation. Such genes include dedicator of cytokinesis 2 (Dock2) [90], or 
integrin alpha M (Itgam, CD11b) [91]. Others which are implicated to be involved in oligodendrocyte 
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maturation, such as insulin-like growth factor 1 (IGF1) [92], or secreted phosphoprotein 1 (SPP1, 
osteopontin) [93] also followed pattern I.  
 
Pattern I genes  
   
Phagocytosis   
GO:0042116; GO:0050766; GO:0006909  
   
Gene symbol Gene name Alternative 
Slc11a1  natural resistance-associated macrophage protein 1 Nramp1 
Fcgr2b  Fc receptor, IgG, low affinity IIb CD32 
Fcgr3  Fc receptor, IgG, low affinity III  CD16 
Vav1  vav 1 oncogene   
   
Cell adhesion   
GO:0007155   
F11r  Junctional adhesion molecule 1 Jam1 
Ly9  lymphocyte antigen 9  CD229 
Itgb2 integrin beta 2    CD18, Mac1b 
Lgals3bp  lectin, galactoside-binding, soluble, 3 binding protein Cycap 
Itgb5  integrin beta 5      
Csf3r  colony stimulating factor 3 receptor (granulocyte)    CD114; G-CSFR 
Spp1  secreted phosphoprotein 1; osteopontin Opn 
Itgam  integrin alpha M    cd11b 
Itgax  integrin alpha X cd11c 
   
Chemotaxis   
GO:0006935; GO:0030593   
Fcgr3  Fc receptor, IgG, low affinity III  CD16 
Itgb2 integrin beta 2    CD18, Mac1b 
Dock2  dedicator of cyto-kinesis 2 MBC 
Ccl6  chemokine (C-C motif) ligand 6 C10 
Csf3r  colony stimulating factor 3 receptor (granulocyte)    CD114; G-CSFR 
Cxcl10  chemokine (C-X-C motif) ligand 10    IP10 
C3ar1  complement component 3a receptor 1   
   
Inflammatory response  
GO:0006955; GO:0006954  
Slc11a1  natural resistance-associated macrophage protein 1 Nramp1 
Fcgr2b  Fc receptor, IgG, low affinity IIb CD32 
Lilrb4  leukocyte immunoglobulin-like receptor, subfamily B, member 4 CD85K 
Irgm1  immunity-related GTPase family M member 1 Lrg-47 
Ccl6  chemokine (C-C motif) ligand 6 C10 
Ly86  lymphocyte antigen 86  MD1 
S1pr3  sphingosine-1-phosphate receptor 3 Edg3 
Cd180  Lymphocyte antigen 78 Ly78 
H2-D1 histocompatibility 2, D region locus 1   
Vav1  vav 1 oncogene   
Serping1  serine (or cysteine) peptidase inhibitor, clade G, member 1 C1-inhibiting factor 
C1qb complement component 1, q subcomponent, beta polypeptide   
C1qc  complement component 1, q subcomponent, C chain   
Oasl2  2'-5' oligoadenylate synthetase-like 2     
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Cxcl10  chemokine (C-X-C motif) ligand 10    IP10 
Clec7a  C-type lectin domain family 7, member a  BGR 
   
Cell proliferation and differentiation  
GO:0021846; GO:0050679; GO:0042127; GO:0030154; GO:0008283  
Fabp7  fatty acid binding protein 7, brain BLBP 
Grn  granulin PCDGF 
Plau  plasminogen activator, urokinase  uPA 
Lgals3  lectin, galactose binding, soluble 3  Mac2 
Lipa  lysosomal acid lipase A    
Ifitm3  interferon induced transmembrane protein 3  Cd225 
   
Regulation of apoptosis  
GO:0043065; GO:0006916; GO:0006917;   
Ptprc  protein tyrosine phosphatase, receptor type, C    CD45 
Igf1  insulin-like growth factor 1     
Tgfbr1  transforming growth factor, beta receptor I     
Spp1  secreted phosphoprotein 1; osteopontin Opn 
   
Lipid metabolism  
GO:0016042; GO:0006631; GO:0016042  
Pld4  phospholipase D family, member 4   
Adfp  adipose differentiation related protein   
Hpgd  hydroxyprostaglandin dehydrogenase 15 (NAD)   pgdh1 
Lpl  lipoprotein lipase      
   
Others   
Cd48    BCM1 
Gas2l3  growth arrest-specific 2 like 3    
Ramp3  receptor (calcitonin) activity modifying protein 3   
Havcr2  hepatitis A virus cellular receptor 2   Tim3 
Cd68  macrosialin Scard1 
Hist1h1c  histone cluster 1, H1c      
Drd1a  dopamine receptor D1A  gpcr15 
Lcp1  lymphocyte cytosolic protein 1 l-plastin 
Prkcd  protein kinase C, delta  pkcd 
Cyth4  cytohesin 4    pscd4 
Nckap1l  NCK associated protein 1 like hem1 
Osmr  oncostatin M receptor    
Klhl6  kelch-like 6 (Drosophila)      
Trem2  triggering receptor expressed on myeloid cells 2   
Csf1r  colony stimulating factor 1 receptor    CD 115; M-CSFR  
Slc15a3 solute carrier family 15, member 3    
Ms4a6c  membrane-spanning 4-domains, subfamily A, member 6C   
Ifit3  interferon-induced protein with tetratricopeptide repeats 3   garg49 
Cst7  cystatin F (leukocystatin)   
Gbp3  nterferon-inducible guanylate binding protein 3   
Gbp2 Interferon-inducible guanylate binding protein 2   
Cd53  CD53 antigen    Tspan25  
Lyn  Yamaguchi sarcoma viral (v-yes-1) oncogene homolog   
Cd52 CD52 antigen CAMPATH-1 
Gusb  glucuronidase, beta      
Capg  capping protein (actin filament), gelsolin-like mbh1 
A2m  alpha-2-macroglobulin     
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Lag3  lymphocyte-activation gene 3    CD223 
Tyrobp  TYRO protein tyrosine kinase binding protein dap12 
Trim30  tripartite motif-containing 30    rpt1 
   
Pattern II genes  
   
Nova1 neuro-oncological ventral antigen 1   
Ndst3 deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 Hsst3 
Cux2 cut-like homeobox 2 Cutl2 
Neurod6 neurogenic differentiation 6 Ath2 
Oscar osteoclast associated receptor   
 
Table 1 
Transcripts altered in remyelination and non-remyelination lesions. Genes are grouped according to their biological 
function given by the Gene Ontology (GO) project. Respective GO numbers are given.  
 
 
4.4 Validation of Affymetrix GeneChip® analysis 
To test the validity of Affymetrix GeneChip® analysis, two different strategies were followed. First, 
we measured the expression of genes reported in the literature to be repressed or induced under 
cuprizone challenge by rtPCR and compared these results with data from the Affymetrix GeneChip® 
evaluation. As expected, rtPCR revealed that demyelination and oligodendrocyte apoptosis lead to the 
rapid down-regulation of oligodendrocyte- and myelin-related genes after acute and chronic 
demyelination. These include myelin oligodendrocyte glycoprotein (MOG), PLP, myelin-associated 
oligodendrocyte basic protein (MOBP), or myelin-associated glycoprotein (MAG). On the other hand, 
expression of inflammatory and stress-response genes, such as GFAP, chemokine (C-C motif) ligand 3 
(CCL3, Mip1α), or chemokine (C-C motif) ligand 6 (CCL6) were dramatically increased. Affymetrix 
GeneChip® evaluation displayed the same regulation pattern (data not shown). Expression of those 
genes being up-regulated in rtPCR analysis were induced in Affymetrix GeneChip® evaluation as well 
and vice versa.  
Secondly, we verified the expression of 6 randomly selected genes following the pro-myelination 
pattern I for Y=20/15 (50%) as indicated in fig. 14. rtPCR expression analysis revealed that 5 out of 6 
genes display the suggested pro-myelination expression pattern I, i.e. abundant expression after acute 
demyelination but low expression after chronic demyelination and in control samples. Genes included 
were adipose differentiation related protein (Adfp), cystatin F (leukocystatin; Cst7), yamaguchi 
sarcoma viral oncogene homolog (Lyn), interferon-induced protein with tetratricopeptide repeats 3 
(Ifit3) and insulin-like growth factor-1 (IGF1) (see fig. 14).  rtPCR analysis revealed that protein 
kinase C, delta (Prkcd) did not follow pattern I expression. Taken together, these results show that the 
applied Affymetrix GeneChip® approach is a valid method to estimate changes in gene expression 
after acute and chronic demyelination. If stricter criteria were applied (Y>20/15), all genes analyzed 
by rtPCR followed pattern I suggesting that this analysis would result in many false negative genes. In 
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contrast, rtPCR analysis revealed increasing numbers of false positive results if weaker criteria 
(Y<20/15) were applied. Therefore, the 50% subgroup is presented.    
 
 
 
 
Figure 14 
Quantitative real-time RT-PCR expression analysis of 6 randomly chosen genes following the pro-myelination pattern I as 
indicated by the array analysis is presented. Each bar represents the averaged fold induction over untreated control mice of 
at least six mice per time point (±SEM). Values were normalized against a housekeeping gene (HPRT) and expressed as % of 
controls (*p<0.05, **p<0.01, and ***p<0.001). Note that 5 out of 6 genes follow the anticipated expression pattern I as 
indicated by the array analysis.  
 
 
4.5 Inflammatory cell composition differs between acute and chronic lesions 
Since most genes following pattern I are related to microglia/macrophages activity, we speculated that 
the acutely demyelinated CC contains more microglia cells compared to the chronically demyelinated 
CC. Therefore, we aimed to characterize lesions used for the array analysis in detail using IHC. As 
shown in fig. 15A, cuprizone exposure induced a severe loss of PLP-reactive fibres and myelinated 
axons (as demonstrated by semi-thin sections) within the CC. The quantitative evaluation of APC+ 
cells within the midline of CC is presented in fig. 15C and shows a significant loss of APC+ 
oligodendrocytes after both acute (p<0.01) and chronic (p<0.001) cuprizone-induced demyelination. 
There is also a trend towards lower numbers of APC+ cells in the chronically demyelinated compared 
to the acutely demyelinated CC, although no significant difference was detectable (fig. 15C). These 
results correspond well with mRNA expression levels of PLP obtained by rtPCR (data not shown). 
During cuprizone-induced demyelination, higher numbers of GFAP+ astrocytes are seen within the CC 
compared to controls (fig. 15A, left column).  
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Figure 15 
Myelination and inflammatory cell composition in the medial corpus callosum (CC) of control (upper row in a), acutely 
(middle row in a), and chronically demyelinated brains (lower row in a) is presented. Brains were fixed at the same time-
point as tissue was dissected for array analysis (i.e. control, 5/13 wks cuprizone followed by 2 days recovery as described in 
materials and methods). Anti-GFAP antibodies were used to visualize astrocytes (1st column in a), anti-PLP antibodies and 
semi-thin sections were used to visualize myelin (2nd and 3rd column in a, respectively), anti-Iba1 antibodies to visualize 
microglia/macrophages (4th column in a), and anti-Mac-3 antibodies to visualize activated microglia/macrophages (5th 
column in a). (B/C/D): Quantification of astrocytes, oligodendrocytes, and microglia cell number is shown, respectively. (E): 
Representative Western-blot analysis of GFAP levels within the entire corpus callosum. (F): Quantification of GFAP protein 
levels. Note that a normal myelination structure in the corpus callosum of control animals can be seen whereas after acute 
and chronic demyelination the midline of corpus callosum is almost completely demyelinated. Large vacuoles within the 
myelin sheaths can be observed in acutely and chronically demyelinated lesions. No difference exists in the number of APC+ 
oligodendrocytes between the acute and chronic lesion as does not for the marked increase in GFAP+ astrocytes. In contrast, 
accumulation of (activated) microglia/macrophages is less extensive after chronic compared to acute demyelination. Scale 
bars: 100 µm in IHC pictures; 2.5 µm in semi-thin sections; *p<0.05, **p<0.01, and ***p<0.001.   
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Number of GFAP+ astrocytes did not differ between the 5 and 13 wk group (fig. 15B). Interestingly, rt 
RT-PCR expression analysis revealed that mRNA transcript levels are significantly higher after acute 
compared to chronic demyelination despite the same number of GFAP+ cells (data not shown). Due to 
the discrepancy of GFAP mRNA levels and GFAP+ cell number, we performed western blotting 
analysis of protein samples isolated from the acutely and chronically demyelinated CC. As shown in 
figs. 15E/F, levels of GFAP protein are higher after acute (~300% induction compared to controls) 
compared to chronic demyelination (~200% induction compared to controls). Microglia/macrophages, 
as detected by Iba1 antibodies, were uniformly distributed in the CC of control animals while a 
sustained increase in Iba1+ cells was present in the demyelinated CC of both treatment groups (fig. 
15A). Quantification of Iba1+ cells showed an increase in both groups, however, the remyelinating CC 
contains a higher number of Iba1+ cells compared to the chronically demyelinated, non-remyelinating 
CC (fig. 15D). Anti-Mac-3 IHC revealed that much more activated microglia cells were present in the 
CC after acute (675 cells per mm2 ± 94) compared to chronic (239 ± 36) cuprizone-induced 
demyelination (right column in fig. 15A). In control animals only a few Mac-3+ cells were visible. In 
summary, it appeared that the active inflammatory infiltrate is more pronounced after acute 
demyelination compared to the chronically demyelinated CC. 
 
4.6 GFAP+ astrocytes strongly express the radial glia cell marker BLBP in acutely but not chronically 
demyelinated lesions 
Some pro-myelination factors cannot be related to differences in microglia activation but are rather 
implicated in astrocyte function such as BLBP/FABP7. We focused on BLBP because it is a highly 
conserved protein in mammals and appears to modulate astrocyte function [63, 94]. We confirmed 
expression pattern of BLBP obtained by Affymetrix GeneChip® array analysis using rt RT-PCR. As 
shown in fig. 16A, expression of BLBP is ~2.5-fold higher after acute but not chronic demyelination 
compared to controls. Next we performed IHC to examine expression of BLBP in acutely and 
chronically demyelinated lesions at the protein level. As shown in figs. 16C/D, few round shaped 
BLBP+ cells were observed within the myelinated CC of control animals. In contrast, numerous 
BLBP+ cells are visible after acute demyelination (fig. 16E/F). Strong BLBP immunoreactivity was 
detected in the cytoplasm and cellular processes. Furthermore, in some cells, BLBP is also expressed 
within the nuclear compartment (arrow in fig. 16F). Those cells were PCNA positive as well, 
indicating proliferation (not shown). In striking contrast, BLBP immunoreactivity is diminished in the 
chronically demyelinated brain despite the abundant presence of GFAP+ cells (figs. 16G/H and 
compare fig. 15A). In those lesions, BLBP protein is mainly located within the cellular processes 
sparing the cytoplasm and nucleus. Immunofluorescence double-labelling revealed that virtually all 
BLBP-expressing cells also express the astrocyte marker GFAP (fig. 16I).  
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Figure 16 
Analysis of BLBP gene and protein expression after acute and chronic demyelination is presented. (A): Analysis of BLBP 
mRNA levels. Each bar represents the averaged fold induction over untreated control mice of at least six mice per time point 
(±SEM). Values were normalized against a housekeeping gene (HPRT) and expressed as % of controls. (B): The medial part 
of the corpus callosum is indicated. (C-H): Effect of acute and chronic cuprizone exposure on distribution of BLBP-positive 
cells within the medial corpus callosum. Cells marked by boxes in (C/E/G) are shown in a higher magnification in (D/F/H). 
Immunofluorescence double-labelling after acute demyelination within the corpus callosum is shown in (I). Appropriate 
secondary antibodies were used to detect the expression of BLBP (red) after acute demyelination and to co-localize it to 
astrocytes (GFAP, green). Yellow indicates co-localization of the red and green fluorochromes in the merged pictures. 
Expression of BLBP is significantly increased after acute demyelination whereas its expression is not induced after chronic 
demyelination compared to controls. Note that BLBP immunoreactivity can be detected within the cytoplasm, cellular 
processes, and nucleus (arrow in F) after acute demyelination. In contrast, BLBP protein is mainly located within the 
cellular processes (arrowhead in H) sparing the cytoplasm and nucleus (star in H) in chronic lesions. Further note that 
virtually all BLBP-expressing cells are also positive for GFAP. Scale bars: 30 µm (C/E/G); 15 µm (D/F/H);   20 µm and 7.5 
µm (I); *p<0.05, **p<0.01, and ***p<0.001.   
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4.7 Expression of BLBP in activated GFAP+ astrocytes strongly correlates with the presence of 
Olig2strong+ oligodendrocyte progenitor cells in the cuprizone model 
We next performed longitudinal studies (control, 1 wk, 2 wks, 4 wks, and 5 wks of cuprizone 
exposure) and analyzed the occurrence of BLBP+ astrocytes during the course of cuprizone-induced 
demyelination. Furthermore, we determined the correlation of BLBP+ astrocytes with (i) the presence 
of mature oligodendrocytes and oligodendrocyte progenitors, and (ii) the magnitude of microglia cell 
accumulation in the medial part of the CC. As shown in figs. 17A-E, number of BLBP+ astrocytes is 
still low after 2 wks cuprizone exposure. However, as expected, number of BLBP+ cells distinctively 
increases till week 5. Mean numbers were 112.9 ± SEM 9.8 cells/mm2 in controls, 295 ± 53.4 at week 
1, 267 ± 42.3 at week 2, 721 ± 78.1 at week 4, and 983 ± 125 at week 5, respectively.  
 
 
Figure 17 
Time dependent changes (control, 1 week, 2 wks, 4 wks and 5 wks cuprizone feeding) of the cellular composition within the 
medial corpus callosum are presented by anti-BLBP, anti-GFAP, anti-Olig2 and anti-Iba1 IHC. Significant accumulation of 
BLBP+- and GFAP+ astrocytes can be detected between week 2 and 4 of cuprizone exposure. More GFAP+ cell processes 
can be seen at week 2 (arrows in H). Severe reduction in Olig2+ cell number is evident at week 1 and 2. Note the 
predominance of Olig2weak+ cells in the corpus callosum of control animals (arrows in K) whereas most oligodendrocytes are 
Olig2strong+ after 5 wks cuprizone exposure (arrows in O). Further note that significant microglia activation can be detected 
already at week 1 as demonstrated by increase in Iba1-positive cell numbers (Q). For quantification of cell parameters see 
Results section. Scale bars: 20 µm;  *p<0.05, **p<0.01, and ***p<0.001.   
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The numbers of GFAP+ astrocytes follow the same trend as observed for BLBP-positive astrocytes 
(figs. 17F-J). Already at week 2, more GFAP+ cell processes are visible indicating astrocyte 
hypertrophy (see arrows in fig. 17H). Number of Olig2+ cells are significantly (p<0.001) decreased at 
week 1 and 2, however, recover till week 5 (figs. 4K-O, p<0.001 week 2 vs. week 5). Mean numbers 
were 2014±168 cells/mm2 in controls, 958±98 at week 1, 927±83 at week 2, 1215±76 at week 4, and 
2249±182 at week 5. Notably, the CC of control animals comprises many Olig2weak+ mature 
oligodendrocytes (arrows in fig. 17K). In contrast, many Olig2strong+ oligodendrocyte progenitor cells 
are present after 5 wks of cuprizone exposure (arrows in fig. 17O). Microglia/macrophages, as 
detected by Iba1 antibodies are uniformly distributed in the CC of control animals while a sustained 
increase in Iba1+ cells is present at week 1 and progresses till week 5 (fig. 17P-T).  
 
 
 
Figure 18 
Regional differences in cellular composition and myelin status between the lateral (left side) and medial (right side) part of 
corpus callosum after 5 wks cuprizone exposure is presented by anti-PLP, anti-Olig2, anti-GFAP and anti-BLBP staining. 
Note that in contrast to the medial part, the lateral part of the corpus callosum is almost completely devoid of any PLP+ 
myelinated axons (A/E) and Olig2+ oligodendrocytes (B/F). Severe astrocytosis can be seen in both parts (C/G). In contrast, 
accumulation of BLBP+ cells is evident solely in the medial (D) but not lateral part (H). Scale bars: 50 µm (A-H). 
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Furthermore, we compared the medial and lateral part of the CC after 5 wks cuprizone exposure. The 
lateral part of the CC is almost devoid of PLP immunoreactivity (fig. 18A, outlined by dashed lines) 
and Olig2+ cells (fig. 18B), whereas the medial part contains some PLP+ axons (fig. 18E) and, as 
already pointed out above, many Olig2strong+ oligodendrocyte progenitor cells (fig. 18F). Distinctive 
astrocytosis, as detected by anti-GFAP IHC, is evident in both parts (fig. 18C/G). In contrast, anti-
BLBP immunoreactivity is just observed in the medial part (fig. 18D/H).  
 
4.8 Expression of BLBP in activated astrocytes appears not to be directly related to the inflammatory 
infiltrate 
To compare accumulation of BLBP-expressing astrocytes in a toxic and an autoimmune-animal model 
of MS spinal cord tissue of SJL mice with PLP-induced relapsing-remitting EAE at different disease 
stages were examined. Clinical signs of relapsing-remitting EAE were first evident on day 9 post-
immunization, and disease symptoms rapidly increased, peaking on day 10 (acute phase). 
Characteristic of relapsing-remitting EAE, this acute phase was followed by a remission (reduction of 
clinical signs). Anti-PLP IHC revealed significant, yet compared to the cuprizone model moderate 
demyelination in spinal cord of animals analyzed during the peak phase (8.91 % of area ± 1.71 given 
in arbitrary units; p<0.05 remission vs. peak) whereas no significant difference of PLP staining 
intensity was observed during the remission phase (17.48 % of area ± 2.15) nor compared to control 
animals (19.12 % of area ± 1.68). Lumbar spinal cord sections were analyzed for GFAP- and BLBP-
expressing cells during the peak phase, remission phase, and in control animals. In the spinal cord 
white matter of complete freud’s adjuvans control mice some GFAP+ cells with radially oriented 
processes towards the pia surface and/or the grey-white matter interface were visible. Occasionally, 
small stellate BLBP+ cells with an astrocyte-like morphology were present in the white matter (mean 1 
cell/visual field±0.2). No inflammatory infiltrate (H&E staining) and only a few Iba1+ cells (8 
cells/visual field ± 1) were seen in control animals (fig. 19A). During the peak phase of EAE, 
prominent foci of spinal cord inflammatory cells (arrow in fig. 19B) and accumulation of Iba1+ 
microglia/macrophages (29 cells/visual field ± 2) were observed in the spinal cord. In these inflamed 
regions, many GFAP+ cells were visible, indicating commencing astrocytosis (fig. 19B). The number 
of BLBP+ cells with an astrocyte-like morphology did not differ compared to controls (2 cells/visual 
field ± 0.7). In sharp contrast, accumulation of BLBP+ astrocytic cells was clearly evident during the 
remission phase of the disease (11 cells/visual field ± 2; p<0.01 compared to controls) besides 
significantly less prominent foci of inflammatory cells (fig. 19C). The number of Iba1+ cells in 
remission phase did not significantly differ compared to the lesions analyzed at the peak of disease (24 
cells/visual field ± 2). Immunofluorescence double-labelling revealed that most BLBP+ cells with an 
astrocyte-like morphology also expressed the astrocytes marker GFAP (data not shown).  
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Figure 19 
Hematoxylin-eosin (H&E) and immunohistochemistry (anti-BLBP, anti-GFAP, and anti-Iba1) from the lumbar anterior 
spinal cord white matter of PLP-induced EAE (SJL) animals is presented. (A): control animal. (B): Animal sacrificed during 
the peak phase of the disease. (C): Animal sacrificed during the remission phase of the disease. The arrow in (B) indicates a 
perivascular inflammatory infiltrate. In control animals, few BLBP+ or GFAP+ cells are visible, whereas several BLBP+ and 
GFAP+ cells are characteristic at the region of pronounced inflammatory infiltrate. However, most pronounced 
accumulation of BLBP+ or GFAP+ cells can be seen during the remission phase with star-shaped BLBP+ and GFAP+ cells 
(inserts in C). Both lesion types (peak and remission) contain numerous Iba1+ microglia/macrophages. Scale bars: 100 µm.  
 
4.9 Number of BLBP-expressing astrocytes in human MS lesions declines with disease duration 
To examine if our findings in mouse models were relevant to human disease, we examined human MS 
samples from early and late disease stages. Since the efficiency of remyelination decreases with age 
and disease duration [95-98], selected post-mortem material of older patients with long disease 
duration (mean age = 67 years;  mean disease duration = 24 years) was compared with early MS 
biopsy lesions of younger patients with short disease duration (mean age = 39 years;  mean disease 
duration = 2.3 months). Furthermore, we compared number of BLBP+ cells between (i) the rim of 
active and chronic active lesion and (ii) the centre of chronic lesions and the NAWM. One 
representative chronic active lesion is presented in fig. 20 although the NAWM is not shown in the 
overview since tissue blocks distant from detectable lesions were examined. The lesion centre, 
indicated in fig. 20A by the upper-box, is devoid of any LFB or anti-PLP reactivity (figs. 20E and H). 
A few HLA-DR expressing cells can be found (fig. 20K). The rim of the lesion (indicated by the lower 
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box in fig. 20A) contains thin PLP+ myelin sheaths (fig. 20G) and numerous activated 
microglia/macrophages (fig. 20J). Within the lesion centre (fig. 20N) as well as in the NAWM (fig. 
20L), very few BLBP+ cells are visible. In contrast, the lesion border contains numerous BLBP+ cells 
with an astrocyte-like morphology (fig. 20M). Numerous cells positive for the oligodendrocyte marker 
Olig2 (both, strong and weak) were present within the NAWM and the lesion border. In contrast, only 
a few are detectable in the centre of chronic active and chronic inactive lesions (figs. 20O-Q). Double-
staining revealed that BLBP-expressing cells are GFAP+-astrocytes (fig. 20R).  
 
 
 
Figure 20 
Photograph of an anti-PLP (A, F-H), Luxol fast blue (LFB)–stained (C-E), HLA-DR (B, I-K), BLBP (L-N), and Olig2-stained 
(O-Q) paraffin-embedded brain tissue section (chronic active lesion) is shown. Upper box in (A) indicates the lesion centre, 
lower box the lesion border, respectively. Number of HLA-DR positive cells is low in the NAWM and the centre of chronic-
active lesions whereas numerous microglia/macrophages are located at the lesion rim. Within the lesion centre some round 
BLBP-positive cells are visible (arrows in l-n are presented in higher magnification as inserts). In contrast, the lesion border 
contains numerous BLBP-positive astrocytes. Numerous Olig2+ cells can be found in the NAWM and at the rim of the lesion, 
whereas the centre of the lesion is almost devoid of Olig2+ oligodendrocytes. Arrow in (Q) indicates an Olig2strong+ 
oligodendrocyte progenitor cell. Co-localization of BLBP and GFAP is demonstrated by immunofluorescence double-
labelling in (R). Scale bars: 3 mm (A/B); 30 µm (C-N), 50µm (O-Q), 2.5µm (R).    
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Representative pictures of biopsy cases are presented in fig. 21. The peri-plaque white matter 
(PPWM), indicated by the lower box in fig. 21A, contains densely-packed PLP+ axons (fig. 21B), 
numerous GFAP-expressing astrocytes (fig. 21E) but only few BLBP+ cells with an astrocyte-like 
morphology (fig. 21H). In contrast, many BLBP+ cells are visible in the centre of the lesion (fig. 21I) 
paralleled by the presence of thin PLP-reactive fibres (fig. 21C) and GFAP+ cells (fig. 21F). 
Quantification of BLBP+ cell numbers are shown in fig. 21J. Since no significant differences in total 
number of BLBP-expressing astrocytes between (i) NAWM of post-mortem tissue and PPWM of 
brain biopsies, (ii) rim of active and chronic-active lesions, and (iii) centre of chronic inactive and 
chronic-active lesions could be observed, those data were pooled. No significant difference in total 
BLBP+ astrocyte numbers was evident between PPWM/NAWM and the centre of chronic 
active/inactive lesions (16.7 ± 3.9 cells/mm2).  
 
 
Figure 21 
Photograph of an anti-PLP (A-C), anti-GFAP (D-F) and anti-BLBP (G-I) stained, paraffin-embedded brain tissue section 
(acute lesion) is shown. Boxes in (A) indicate regions shown in (B/C, E/F and H/I) in higher magnification. The upper box 
indicates the region with intense remyelination, the lower the peri-plaque white matter (PPWM). In (J) quantification of 
BLBP+ astrocytes in the normal appearing white matter (NAWM) and peri-plaque white mater (PPWM), the remyelination 
areas of biopsy human MS material (biopsy), the rim of active and chronic active lesions (rim), and the centre of chronic 
active and chronic inactive lesions (centre) is presented. Highest number of BLBP+ astrocytes is found within remyelination 
areas of brain biopsies. Scale bar: 1 mm (A/D/G); 30 µm (B/C, E/F, H/I); *p<0.05, **p<0.01 and ***p<0.001.   
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Most BLBP+ astrocytes can be found in demyelinated tissue of biopsy samples (149.2 ± 20.28 
cells/mm2; compare figs. 21H/I), significantly more compared to the rim of (chronic)-active lesions 
(90.4 ± 20.2 cells/mm2). BLBP-expressing astrocytes were hardly present within the centre of active 
lesions or in shadow-plaques in post-mortem tissue.  
 
4.10 Expression of BLBP in U87 astrocytoma cells regulates FGF2, PDGF-AA and SPP1 but not 
IGF1 mRNA expression 
It has been reported that BLBP might regulate gene expression [99]. We speculated that BLBP levels 
in astrocytes might influence expression of growth factors involved in oligodendrocyte maturation, 
such as IGF1, FGF2, PDGF-AA, or SPP1. To test this hypothesis, the BLBP-negative malignant 
glioma cell line U87 was stably transfected using a BLBP expression construct as reported previously 
[63] and expression of the four growth factors was analyzed using rt RT-PCR. As shown in fig. 9A, no 
expression of BLBP mRNA can be detected in control  U87 cultures, whereas U87 cells, transfected 
using a human BLBP construct, express relevant levels of BLBP mRNA. As shown in fig. 22B, IGF-1 
is not expressed in either controls or BLBP-transfected U87 cells. In contrast, levels of FGF2 (100 ± 3 
vs. 187 ± 15; p<0.01), PDGF-AA (100 ± 17 vs. 172 ± 25; p<0.05) and SPP1 (100 ± 9 vs. 231 ± 15; 
p<0.01) mRNA are significantly higher in BLBP-transfected cells when compared to control cultures.  
 
 
 
 
 
Figure 22 
Expression of growth factors IGF1, FGF2, PDGF-AA and SPP1 in BLBP+ and BLBP- U87 malignant glioma cells is 
presented. Values were normalized against a housekeeping gene (18s) and expressed as % of non-transfected controls. (A) 
demonstrates high levels of BLBP mRNA in transfected cells (right side) compared to control cultures (left side). Note that 
mRNA levels for FGF2, PDGFAA and SPP1 are significantly higher in BLBP-transfected U87 cells when compared to 
controls; *p<0.05, **p<0.01 and ***p<0.001.   
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Discussion 
The results of my thesis can be summarized as follows: 
 
i.)  The cuprizone model reflects several features of multiple sclerosis histopathology and, maybe, 
pathogenesis, as well. 
ii.) Brain region specific inflammatory responses are a critical link between oligodendrocyte stress 
and subsequent fulminant demyelination. 
iii.) Myelin loss and, in consequence, myelin debris are important parameters for brain-intrinsic 
inflammatory responses. 
iiii.) Brain lipid binding protein appears to be critically involved in endogenous remyelination 
processes.  
 
 
In the following chapter, I would like to critically discuss our major findings and relate them to the 
current knowledge.  
 
1. The cuprizone model as a tool to study demyelination  
As pointed out already in the introduction, profound heterogeneity in the pattern of demyelination 
among MS patients exists [20, 100], at least in the initial disease stage. In respect of the cuprizone 
model, pattern III lesions are from great interest. Within these areas, myelin-forming oligodendrocytes 
show nuclear condensation and fragmentation which are typical signs of apoptosis. Some authors state 
that the histopathological pattern of cuprizone-induced demyelination resembles type III lesions [101]. 
Indeed, there are some similarities between both forms. MAG mRNA levels seem to be more down-
regulated during early demyelination compared to other myelin protein markers [102], demyelination 
does not present in a perivenous distribution, borders are ill-defined, and pronounced oligodendrocyte 
apoptosis can be found in active demyelinating lesions [3]. However, other features of pattern III 
lesions, such as inflamed blood vessels and the presence of CD3+ T cells, are not observed in the 
cuprizone model. The later might be due to a direct suppression of cuprizone on T cell function [103, 
104]. The question arises, whether cuprizone-induced demyelination models myelin loss observed in 
MS patients. This assumption is often challenged by experts in the field. The “perfect” MS animal 
model does not exist. We want to stress that MS is presently regarded as a disorder with many 
different features and facets. No current experimental animal model covers the entire complexity of 
MS in humans. Instead, the various animal models and intoxications can be applied to selectively 
investigate and uncover distinct pathological processes and repair mechanisms of MS [3]. Cuprizone 
intoxication is a straight forward model to investigate brain-intrinsic inflammatory responses, i.e. 
microgliosis and astrocyte activation. Furthermore, this model can be fruitful in deepening our 
understanding of remyelination and its failure, as shown by several groups [12, 105, 106].  
In this study, we compared histopathological features of the cuprizone model with MS tissue samples. 
Cuprizone ingestion in mice induces a highly reproducible demyelination of distinct brain regions, 
among them the CC which represents the most frequently investigated white matter tract in this animal 
model [12, 52, 107]. After 5–6 wks of cuprizone treatment, the CC is almost completely demyelinated, 
a process called “acute demyelination”. Acute demyelination is followed by spontaneous 
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remyelination during subsequent weeks when mice are fed normal chow. In contrast, remyelination is 
highly restricted when cuprizone administration is prolonged (12 wks or longer), a process called 
“chronic demyelination”. During late stages of acute demyelination, spontaneous remyelination occurs 
partially but fails under a continued cuprizone challenge [3]. Our group was able to show that other 
regions are affected as well. Norkute and colleagues reported that cuprizone treatment induces 
demyelination and astrocytosis in the mouse hippocampus [29]. However, no significant effect on 
microglia invasion was detected at any investigated time point (0, 3, 5, and 7 wks). In my thesis I was 
clearly able to show that distinct hippocampal subregions display significant microgliosis such as the 
medial alveus or fimbria region at week 5 (see chapter 1). As pointed out above, the magnitude of 
microgliosis progressed in the CC until week 5, whereas a reduction of microglia cell numbers could 
be observed in the fimbria after 2 wks cuprizone exposure (compare fig. 6). Furthermore, microgliosis 
is sparse in the affected grey matter. Due to the fact that A. Norkute mainly focused in her work on 
hippocampal grey matter structures and included a 3 wks cuprizone period as the earliest time point, 
early microgliosis might have been missed [29].  
As already reported by Geurts and colleagues, hippocampal demyelination is frequent and extensive in 
MS [68]. We observed hippocampal demyelination to be a frequent phenomenon, as well. In the 
current study, we investigated the inflammatory response (i.e. microglia activation) within 
hippocampal white and grey matter regions of MS patients. Affected white matter regions displayed a 
more severe accumulation of LN3-expressing microglia/macrophages compared to demyelinated grey 
matter parts. One should note that in MS lesions, LN3+ cells might originate either from brain resident 
microglia cells or recruited peripheral monocytes. Currently, no reliable marker can differentiate 
between both cell types. In cuprizone-induced demyelination it has recently been shown that 
peripheral monocytes are not recruited to the side of tissue injury [108], thus, Iba1+ cells represent 
activated and/or recruited brain-resident microglia. Future studies have to show whether recruitment of 
peripheral monocytes differs between white and grey matter lesions in MS.  
Pott and colleagues were able to demonstrate that cuprizone intoxication induces a severe 
demyelination of distinct cortical deep grey matter sub-regions. Striosomes, located within the 
caudate-putamen and the ventral part of the caudate nucleus displayed intense demyelination, whereas 
those within the globus pallidus and the head of the caudate nucleus were not affected. The matrix 
region was equally affected in the medial and lateral region [67]. My thesis shows for the first time to 
my knowledge that the two key findings in the cuprizone model (i.e. (i) preserved striosomes in 
regions distant to the ventricles and (ii) equal demyelination of the matrix region irrespective of their 
anatomical location) are relevant for MS. We were able to show that 8 out of 19 analyzed human basal 
ganglia lesions (i.e. striatal lesions) displayed a partial or complete preservation of myelinated axons 
within the striosomal compartment (figs. 5C/D). In contrast, the matrix is almost completely 
demyelinated (figs. 5G/H). Also not presented within the results section, combined striosome-matrix 
demyelination was another frequently observed phenomenon in MS. Future studies have to show 
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whether extend of striosome demyelination can be related to ventricular distance. If so, protective 
ingredients within the liquor might be considered being protective in MS.  
2. Mechanism of cuprizone-induced demyelination 
The underlying mechanisms of cuprizone-induced oligodendrocyte cell death are not fully understood. 
It has been assumed that a cuprizone-induced copper deficit might be detrimental to mitochondrial 
function in the brain [33] and that it is a disturbance of energy metabolism in oligodendroglia and cell 
function that leads to demyelination [3, 15]. Why oligodendroglia should be preferentially susceptible 
to copper deficit is not known, although an obvious hypothesis is that the perikaryon of this cell type 
has to maintain a vast expanse of myelin and this extraordinary metabolic demand places it in jeopardy 
if the demand cannot be met. Our data, however, do not support this hypothesis. We were clearly able 
to show that perineuronal satellite oligodendrocytes are equally vulnerable to cuprizone-induced 
demyelination compared to myelinating oligodendrocytes in the cortex. Reductions for both cell 
populations where approximately -75% (compare figs. 8E/F). Satelite oligodendrocytes are assumed to 
be non-myelinating cells in normal brains, but support adjacent neurons [109]. Our results suggest that 
oligodendrocyte specific toxicity of cuprizone is not linked to the metabolic demand of myelinating 
oligodendrocytes. Lack of detailed knowledge of the molecular details of the point of pathological 
action targeted by copper deficiency remains frustrating, as is our lack of knowledge as to the reason 
for preferential susceptibility of oligodendroglia in this model [15]. 
3.  What determines microglia activation? 
In the current study (chapter I and III) we investigated the relationship between amount of myelin 
debris (i.e. myelin loss) and microglia activation and astrocytosis in the cuprizone model. 
Furthermore, we determined microglia/macrophage activation in MS cortical lesions. We focused on 
Type 1 lesions since lesion “activity” can readily be determined by analyzing the white matter part. 
Our major finding was that extend of myelin loss is the major predictor for the degree of 
microglia/macrophage activation. Cortical layers with a priori sparse myelin content, such as layer 1 
of the pScx displayed no significant increase in microglia cell numbers whereas cortical areas with an 
a priori high myelin content under control conditions, such as layer 6 of the pScx, displayed intense 
microgliosis. Microglia activation and accumulation was most pronounced in the white matter tract 
CC where the degree of myelin loss was highest. These observations are in line with results from 
others [110]. Furthermore, we were clearly able to demonstrate that both, grey and white matter areas 
in Type 1 MS lesions, display inflammatory activity. Comparable to our results using the cuprizone 
model, we found less pronounced microglia activation in the grey matter compared to the white matter 
part of Type 1 lesions. Thus, it appears that the degree of microgliosis in MS lesions is mainly dictated 
by the extend of myelin loss, at least in Type 1 lesions. The observation of higher local HLA-DR cell 
numbers within the demyelinated Gennari stripe strengthens our hypothesis.  
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Although MS has been classically thought of as a white matter disorder, the involvement of grey 
matter regions was acknowledged in early pathology studies [35].  Since the introduction of myelin 
IHC, such as anti-PLP or anti-MBP, demyelination of grey matter regions as an important feature in 
MS pathology has received new impetus. Clinically, grey matter demyelination is of importance. For 
example, MS patients with cognitive decline have more cortical damage than patients who are 
cognitively preserved. In one study, there were positive correlations between cortical volume values 
and performance in verbal memory, verbal fluency and attention/concentration testing in cognitively 
impaired MS patients [111]. In a later published study, the same group was not able to find any 
correlation between brain volume changes, deep grey matter volume or changes in lesion load on T2-
weighted magnetic resonance imagings (MRIs) and cognitive impaired MS patients. However, 
patients with cognitive impairment displayed less cortical volume compared to cognitively preserved 
MS patients [112]. Thus, progressive neocortical grey matter loss is likely to be relevant for MS-
associated cognitive impairment.  
Based on their location, cortical grey matter lesions are named either Type 1 lesions (mixed white 
matter-grey matter lesions), Type 2 lesions (purely intracortical lesions), or Type 3 lesions (subpial 
lesions) [23-26]. Type 3 lesions are most common and can extend over several gyri to involve almost 
all sampled cortical areas [22, 23, 113]. Furthermore, it has been reported that cortical demyelination 
is a characteristic feature of progressive MS and is rare or absent in patients with acute or relapsing 
disease [22].  
In our study, 26 out of 167 tissue blocks (~15%) contained cortical Type 1 lesions. Following the 
autopsy procedure at the VU University Medical Center, tissue blocks were selected on the basis of 
signal intensity changes in the white matter at post-mortem T2-weighted MRI [113, 114]. Thus, our 
sampling protocol is biased towards myelin abnormalities and, therefore, might overestimate the actual 
extend of Type 1 lesions in progressive MS cases. An even higher frequency of cortical Type 1 lesions 
has been reported by another group [24]. In their study, 38 of 110 tissue blocks (~34.5%)  contained 
cortical Type 1 lesions [24]. In summary, breakthrough of white matter lesions into the grey matter is, 
obviously, a frequent phenomenon, at least during the progressive disease stage. Several studies 
investigated a possible correlation between cortical demyelination and white matter changes in MS. It 
was suggested that cortical lesions are independent of the presence of white matter lesions [22, 113]. 
However, the emergence of cortical Type 1 lesions appears to be closely associated with white matter 
pathology. It remains to be clarified whether cortical Type 1 lesions emerge in the grey matter and 
spread into the white matter or vice versa. However, several observations suggest that the later is true. 
First, the white matter part of most lesions included in this study was by far greater compared to the 
grey matter part. Second, in some tissue blocks we observed demyelination of deep cortical layers 
nearby active white matter lesions. Since those lesions do not fulfil the criteria of a “classical” Type 1 
lesion, i.e. continuous demyelination of white and grey matter parts, they were not included in the 
current study. Third, we observed that several so called cortical “Type 4” lesions, extending 
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throughout the full width of the cerebral cortex, end at the white-grey matter junctions. Although a 
mild inflammatory reaction was observed within the nearby white matter, demyelination was not 
evident. This suggests that inflammatory white matter affects grey matter integrity. Findings from 
Peterson and colleagues [24] highlight the clinical importance of this “white matter attack” at cortical 
grey matter being evident in Type 1 lesions. They reported transacted axons, transacted dendrites and 
apoptotic neurons in demyelinated cortical grey matter and observed that the numbers of transsected 
neurites correlated with the inflammatory activity of the lesions. Further studies have to show whether 
Type 1 lesions correlate with clinical disability in MS.  
Studies on the pathogenesis of grey matter lesions suggest that its underlying disease mechanisms 
differ between grey and white matter lesion. It has been reported that lymphocyte infiltration is a 
feature of white but not grey matter lesions. The highest density of CD3+ T cells was found in MS 
white matter lesions. Fewer T cells were detected in cortical lesions that extended through both white 
and grey matter (i.e. Type 1 lesions). The lowest number of T cells was detected in intracortical 
demyelinated lesions (i.e. Type 2 lesions). A similar distribution was found using the CD4, CD8, and 
CD45RO markers [25]. Brink and colleagues investigated complement deposition in white and grey 
matter MS lesions. Whereas complement deposition was abundant in white matter lesions, 
significantly less was observed within the affected grey matter. In purely cortical lesions, the extent of 
complement deposition in general was lowest [21]. Van Horssen and colleagues recently reported that 
although blood-brain barrier (BBB) dysfunction is a common feature of white matter MS lesions, 
cortical MS lesions lack markers for BBB disruption [26]. However, some Type 1 lesions displayed 
BBB deficits such as serum protein leakage. Taken together, the higher inflammatory phenotype of 
active Type 1 grey matter lesions is paralleled by a close overlap with the pathology of white matter 
lesions.  However, those tissue alterations are less severe in the grey compared to the white matter. 
Microglia cells can modulate all of the described parameters. It has been reported that microglia can 
potentiate damage to the BBB [115-117] and can modulate, together with astrocytes, lymphocyte 
trafficking [92, 118]. One might speculate that described differences in white and grey matter 
pathology might be due to the deficiency of myelin-driven microglia response.    
In summary, our data demonstrate the importance of myelin loss for microglia activation in both, the 
white and grey matter. It appears that lack of inflammation in grey matter lesions might be either due 
to lesion inactivity (i.e. chronic lesions) or low myelin loss, especially in superficial cortical layers. 
Further studies have to show whether activated microglia actively regulate white matter features in the 
grey matter, such as lymphocyte infiltration or BBB damage.  
4. The cuprizone model as a tool to study remyelination 
In this study, we took advantage of the toxic de- and remyelination cuprizone model. In this model, 
feeding of cuprizone to young adult mice induces oligodendrocyte cell death which is closely followed 
by microglia and astrocytes activation [3]. Due to an intact BBB, peripheral cell recruitment does not 
occur [108]. It has been postulated that remyelination completely fails after a chronic demyelination 
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(13 wks) event [53, 119], whereas other reports suggest that remyelination does not completely fail but 
is delayed [120]. In our study, we did not observe any recovery in myelin staining intensity after a 4 
wks recovery period. We cannot exclude that remyelination would have been evident after a longer 
recovery period or using more sensitive techniques such as electron-microscopy. However, it is 
obvious that remyelination is at least impaired after prolonged cuprizone exposure.   
Remyelination can be classified as four consecutive steps: (i) proliferation of oligodendrocyte 
progenitor cells, (ii) migration towards the demyelinated axons, (iii) differentiation and, finally (iv) 
interaction of the premature oligodendrocyte with the axon (i.e. axon wrapping) [95]. There are likely 
to be many factors contributing to the eventual failure of remyelination in MS and the essential 
processes of progenitor recruitment, differentiation, axon-oligodendrocyte interaction and myelination 
itself may all be adversely affected albeit to differing extents by a changing lesion environment and 
increasing levels of axonal compromise. After 5 wks cuprizone treatment several features of 
remyelination are evident on the histological level. This is best demonstrated by our finding that many 
Olig2strong+ OPCs have already been recruited to the midline of the CC at week 5, indicating that 
proliferation of OPCs and migration of those towards demyelinated areas is already in progress 
(compare figs. 17O and 18F). This observation is in line with findings from other groups [75, 110, 
121, 122]. We can, therefore, not exclude that our experimental approach is biased towards those 
factors regulating differentiation rather than proliferation and migration of progenitor cells. 
Nevertheless, in light of findings that remyelination appears to be limited due to a disturbed 
differentiation of oligodendrocyte progenitor cells, findings of our Affymetrix®-analysis might 
identify new factors related to this differentiation block [45-47, 123].  
5. Identification of ongoing remyelination 
Remyelination areas are classified according to a set of histopathological criteria. In general, 
remyelination plaques are areas with reduced myelin staining intensity showing thin, irregularly 
formed myelin sheaths. According to Kuhlmann and colleagues [124] remyelinating lesions are 
infiltrated early on in MS by numerous macrophages and T cells, while remyelination plaques from 
chronic MS patients are characterized by a mild inflammatory reaction [124]. The presence of 
microglia or macrophages containing LFB or MOG-positive myelin breakdown products indicates 
persisting demyelination rather than remyelination. Patani et al.  [125] highlight that neurofilaments 
should be visualized to ensure that reduced myelin staining intensity is not due to reduction of axonal 
density while Prineas and Connell [83] define a remyelinated plaque as a demyelinated area which (i) 
contains myelin and (ii) does not show macrophages containing LFB, MBP or CNPase-positive 
material although lipid-loaded PAS-positive foamy macrophages can be present [83]. Thus, it is 
almost impossible to identify ongoing remyelination in cross-sectional histological studies. The 
presence of remyelinated axons in for example so called “shadow-plaques” simply indicates that 
remyelination has occurred at a certain time point.  
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It is believed that remyelination is especially prominent at the early stages of MS and sparse after 
several years of disease duration [98]. Furthermore, several pathological studies have suggested that 
chronic lesions typically display limited remyelination that is restricted to the plaque periphery [83, 
126]. To study expression of BLBP in early and late activated astrocytes in the context of 
remyelination capacity we followed two different strategies. First we compared BLBP expression 
levels and number of BLBP+ astrocytes after acute and chronic cuprizone-induced demyelination. 
Recent astrocyte activation has occurred in the acutely demyelinated group (compare results from our 
longitudinal studies) whereas prolonged astrocyte activation is evident in the chronically demyelinated 
group. This is in line with observations from other groups [127]. Second, number of BLBP-expressing 
astrocytes was analyzed in patients with quite short (i.e. biopsy cases) and long (i.e. post-mortem 
tissue) disease duration, respectively. Furthermore, we compared BLBP expression between the rim 
and centre of chronic active lesions. Remarkably, numbers of BLBP+ astrocytes are highest in lesions 
obtained from young patients with short disease duration where remyelination is thought to be most 
effective [95-98]. In line with this finding, numbers of BLBP+ astrocytes are significantly higher after 
acute compared to chronic cuprizone-induced demyelination. One might speculate that BLBP 
expression simply marks activated astrocytes. While we can not completely rule out this possibility 
our data suggest that this is not the case. As shown in fig. 18, both parts of the CC contain activated 
astrocytes as indicated by anti-GFAP IHC. However, only astrocytes within the medial part of the CC 
express BLBP. Furthermore, activation of the astrocyte population is evident during the peak phase of 
PLP-induced EAE, whereas BLBP expression is still weak (compare fig. 19). A possible relevance of 
BLBP-expressing astrocytes for remyelination is highlighted by our observation that Olig2strong+ OPCs 
are abundantly present in the medial part but almost absent in the lateral part of the CC at week 5. We 
rather suggest that BLBP expression by activated astrocytes occurs during the initial disease stages 
and declines as disease progresses. Thus, two astrocyte phenotypes can be distinguished: (1) GFAP 
positive astrocytes with high BLBP expression and (2) GFAP positive astrocytes with no/low BLBP 
expression. While regional differences of astrocyte function should be considered in this context [59] 
further studies are needed to show whether myelin debris directly induces expression of BLBP in 
activated astrocytes. This could be either by direct myelin debris-astrocyte interaction or indirectly by 
a modulation of microglia [128]. Several in vitro studies demonstrated that myelin phagocytosis by 
microglia and macrophages triggers release of proinflammatory cytokines and nitric oxide [129, 130]. 
Cytokines could subsequently induce or potentiate BLBP expression in astrocytes.  
6. Relevance of inflammation for remyelination 
The data from the gene expression studies and IHC findings indicate that the inflammatory response is 
critical for endogenous remyelination. The importance of inflammation for endogenous remyelination 
is well-documented [125]. The cytokines TNFα (mediated by the TNFα receptor 2) and interleukin 1β 
promote proliferation of OPCs and remyelination [50, 51]. Major histocompatibility complex-II-
deficient mice display delayed remyelination and regeneration of oligodendrocytes compared to their 
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wild type littermates after cuprizone or Theiler's virus-induced demyelination [131, 132]. Furthermore, 
the activation of an inflammatory response by a combination of growth factors leads to myelin repair 
[133]. This shows a beneficial role for inflammatory responses in the CNS. Other factors related to 
inflammation, such as interferon-gamma [4, 134], however, might be detrimental for remyelination. 
The understanding of the dual role of inflammatory cytokines/factors represents a major goal for the 
development of new therapies. Abundant expression of factors being classified as potential pro-
myelination factors (see fig. 13) might be related to myelin digestion by microglia at week 5 whereas 
phagocytic microglia are certainly less abundant in the chronically demyelinated brain. Further studies 
are necessary to elucidate whether phagocytosis of myelin by microglia is paralleled by release of 
growth factors from those cells.   
7. Astroglia: general remarks 
It is well-known that glial cells are more than “glue”-material between neurons, a “function” originally 
suggested by Rudolf Virchow in the mid 19th century. Astrocytes represent a subpopulation of 
macroglia in the peripheral and central nervous system. Since the late nineteenth century, astrocytes 
have been divided based on their morphology into two main subtypes: protoplasmic (lat. astrocytus 
protoplasmaticus) and fibrous astrocytes (lat. astrocytus fibrosus). Protoplasmic astrocytes are present 
throughout the grey matter and exhibit morphological characteristics such as several stem branches 
that, in turn, give rise to finely branching processes in a uniform globoid distribution. In contrast 
fibrous astrocytes are found throughout the white matter and display many long fibre-like processes 
(from Ramon Y, Cajal S; 1909: Histologie du systeme nerveux de l’homme et des vertebres). Astroglia 
function exceeds by far a solely supportive role in neural tissue. These cells are dynamic, capable of 
communicating with neurons and other glial cells. Their processes extend to neuronal synapses, nodes 
of Ranvier, and to the BBB, and they are interconnected via gap junctions to each other as well as to 
oligodendrocytes [135, 136]. Astroglia are essential for the physical structuring of the brain, 
metabolism, and synaptic functioning in addition to their role in responding to pathological insults. 
Such insults provoke a graded cellular activation referred to as reactive gliosis [137, 138]. There is a 
growing body of evidence suggesting that the loss of normal astrocyte function or acquisition of non-
physiological properties contribute to, or are even considered as, the primary cause of the genesis of 
human brain diseases. Alexander disease (AD) represents one of those disorders linking astrocyte 
dysfunction with disease pathogenesis [139-141]. AD is a progressive, usually fatal neurological 
disorder, and can be divided into an infantile, juvenile, and adult form. Although all three forms of AD 
can differ markedly in their clinical, para-clinical, and pathological presentation, they are united by the 
abundance of so-called “Rosenthal fibres” which are protein aggregates within astrocytes composed of 
GFAP, αB-crystallin, and heat shock protein 27 [142]. AD is a rare genetic disorder caused by 
mutations in the gene for GFAP - a type III intermediate filament protein transcribed from a 10 kb 
region located on chromosome 17 in humans and 11 in the mouse. Mice lacking this intermediate 
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filament protein still display normal development and reproduction [143]. In contrast, astrocytes of 
transgenic mice with an over-expression of the human GFAP gene, reveal inclusions resembling 
Rosenthal fibres [144]. Following these interesting findings, Brenner and colleagues showed that 
heterozygous miss-sense mutations of GFAP are associated with AD, establishing this rare disorder as 
the first example of a primary genetic disorder of astrocytes [145]. Another example of a dysfunction 
of astrocytes associated with brain pathology is neuromyelitis optica. Neuromyelitis optica (NMO or 
Devic's disease) is a severe autoimmune inflammatory and demyelinating disease of the CNS which 
predominantly affects the spinal cord and the optic nerve [146, 147]. Although previously referred  to 
as a subtype of MS, the recent description of NMO-IgG, a highly disease-specific autoantibody found 
in NMO but absent in the classical form of MS, convincingly demonstrated that NMO is a specific 
disease and not just a subtype of MS. The target antigen of NMO-IgG was identified as aquaporin-4 
(AQP4), the main water channel protein in the CNS, expressed on astrocyte end-feet at the BBB and 
brain-cerebrospinal fluid-barrier [148]. AQP4 plays a crucial role in the regulation of water fluxes 
from the extra- to the intracellular compartment in the CNS. A series of clinical and pathologic 
observations strongly suggest that auto-antibodies directed against astrocytic AQP4 play a central role 
in the physiopathology of NMO [149].  
8. BLBP expression in astrocytes 
Notwithstanding the importance of microglia/macrophages in the context of remyelination [55], we 
focused on the distribution of BLBP-expressing astrocytes. Schmid and colleagues [150] used 
fluorescence transgenic mice under the control of the BLBP promoter to study the cellular distribution 
and morphology of BLBP-expressing cells. They were able to show that during the early postnatal 
days, radial glia transform into GFAP+ astrocytes in which the BLBP promoter remains active. 
Consistent with this, they observed BLBP expression in GFAP+ astrocytes of the adult cerebral cortex 
and hippocampus. BLBP/GFAP double-positive cells were primarily found in the outer layers of the 
cortex to the pial surface and in cells distributed adjacent to the ventricles [150]. These observations 
are in good agreement with our results. Samples of control mice and NAWM in MS contain 
GFAP+/BLBP+ cells within the subpial compartment and next to the ventricular wall.  
Recent reports suggest that BLBP might be involved in CNS pathology during adulthood. Studies of 
BLBP expression in neurological disorders reveal that expression is increased within different 
hippocampal sub-regions in response to cerebral ischemia [151]. In another study, three single 
nucleotide polymorphisms from BLBP showed an association with bipolar disorder [152]. 
Furthermore, it has been demonstrated that BLBP is expressed in astrocytoma and some malignant 
glioma cell lines. Cytoplasmic expression correlated with metastasis properties of those malignancies 
[63]. BLBP expression is found in pure glioblastoma histology and associated with reduced survival. 
Nuclear expression of BLBP was related to more invasive tumors [153, 154].  
To our knowledge, only one other study investigated the distribution of BLBP-expressing astrocytes in 
MOG-induced EAE [89]. Here the authors recently demonstrated that BLBP/GFAP double-positive 
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cells accumulate within the spinal cord. During disease course, they observed large, multiprocess-
bearing BLBP-expressing cells. It was suggested by the authors that migration of oligodendroglial 
lineage cells into the lesions is retarded by the intense peri-lesional gliosis. Our results, however, 
indicate a rather beneficial function of BLBP expression in astrocytes.   
9. Possible role of BLBP for astrocyte-mediated oligodendrocyte maturation 
To gain insight into underlying mechanisms of BLBP-mediated tissue repair, we stably transfected 
U87 malignant glioma cells with a human BLBP construct to investigate the relevance of BLBP-
expression for growth factor expression. We selected IGF1, FGF2, PDGF-AA and SPP1 since all four 
peptides are well-known to modulate oligodendrocyte proliferation, maturation, or remyelination [93, 
155, 156]. In vitro ligand binding studies have shown that the polyunsaturated fatty acid (PUFA), ω-3 
docosahexaenoic acid (DHA; 22:6) is the preferred ligand of BLBP. BLBP also binds ω-6 arachidonic 
acid (AA; 20:4), albeit with a ~4-fold lower affinity [157]. Fatty acid binding proteins, among BLBP, 
are able to regulate intracellular levels and localization of fatty acids. Fatty acids, in particular PUFA 
are able to act as second messengers. They may substitute for the classical second messenger inositide 
phospholipid and the cyclic AMP signal transduction pathway. Furthermore, in mammals, the 
expression of many genes has been shown to be modulated by fatty acids in a positive or a negative 
manner. Several transcription factors, among peroxisome proliferator-activated receptor (PPAR) could 
mediate fatty acid effects [99, 158]. Whether BLBP stimulates growth factor expression by interfering 
with second messenger signalling cascades or by direct modulation of transcription factors, such as 
PPARs remains to be clarified.  
Another attractive concept how BLBP expression in activated astrocytes might modulate tissue repair 
is by positively influencing cell migration and cell motility. Highly unsaturated long-chain fatty acids 
alter the structure and function of membranes, increasing their fluidity and elasticity [159-161]. 
Preferential localization of BLBP at the leading edges of astrocytes may result in increased PUFA 
content at these sites. Increased fluidity may directly promote cell motility or may activate cell 
signalling events associated with cell motility und thus further diminish the gap between 
oligodendrocyte progenitors and astrocytes processes. Mita and colleagues were able to demonstrate 
that expression of BLBP in BLBP- malignant glioma cells is accompanied by increased migration and 
extended cell processes. Conversely, BLBP depletion in BLBP+ malignant glioma cells results in 
decreased migration, reduction in cell processes, and a more transformed phenotype [63]. 
In summary, we provide evidence that expression of BLBP negatively correlates with disease duration 
and in parallel with failure of remyelination. A direct contribution of BLBP-expression in activated 
astrocytes to myelin repair, however, remains to be verified.   
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Appendix  
 
Appendix 1: Transcardial perfusion of mice 
 
Fixative 
 
- Boil 800 ml of bi-distilled water 
- Dissolve 3.3 g NaH2PO4xH2O (Natriumdihydrogenphosphat-Monohydrat, Carl-Roth, 
Germany) and 45 g Na2HPO4x12H2O (di-Natriumhydrogenphosphat-Dodecahydrat, Carl-
Roth, Germany) 
- Dissolve 20 g paraformaldehyde (Sigma-Aldrich; Germany) 
- Add 100 ml saturated picric acid (Sigma-Aldrich; Germany) 
- Let cool to room temperature, set pH to 7.4 and add bi-distilled water to 1000 ml 
- Filter and cool to 4 °C 
 
Procedure 
 
- 30 min prior to start, apply 10 µl Clexane-40mg (Sanofi-aventis, Germany) by intraperitoneal 
injection 
- Deeply anaesthetise animals with Isolfuran (5%, Abbott, Germany) 
- Fix the animal in supine position, open the thorax by using forceps and scissors and cut a 
small opening into the right atrium of the heart 
- Insert a small needle into the left ventricle of the heart and perfuse 50 ml of ice-cold perfusion 
solution 
- Cut the head and/or the trunk 
- Incubate the tissue samples overnight at 4 °C in the same fixative 
- Dissect the brain/spinal cord and store in one to five diluted fixative at 4 °C till the paraffin-
embedding procedure 
 
 
Appendix 2: Paraffin-embedding of mice tissue samples 
 
Since paraffin is immiscible with water, the main constituent of most tissue blocks need to be 
dehydrated by progressively more concentrated ethanol baths. This is followed by a clearing agent, 
usually xylene or less toxic substitutes such as Histo-Clear, to get rid of the ethanol. Finally, molten 
paraffin wax infiltrates the sample and replaces the xylene/substitute. 
 
 
Tissue samples were embedded in paraffin by immersing them under gentle agitation for the desired 
time in 
 
- 70% Ethanol:    3 x 30 min 
- 96% Ethanol    3 x 30 min 
- 100% Ethanol    3 x 30 min 
- Histo-Clear (Biozym, Germany) 3 x 60 min 
- Parrafin (VWR, Germany)  3 x 120 min and then overnight at 60 °C 
 
Thereafter, tissue samples were blocked in paraffin and processed following standard protocols.  
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Appendix 3: Immunohistochemistry 
 
Immunohistochemistry is a method for demonstrating the presence and location of proteins in tissue 
sections. In our lab, we routinely use paraffin-embedded material for the detection of proteins in brain 
tissue. Immunohistochemical stainings are accomplished with primary antibodies that recognize the 
protein of interest. Since antibodies are highly specific, the antibody will bind only to the target 
protein in the tissue section. The antibody-antigen interaction is subsequently visualized using either a 
chromogenic detection system, in which an enzyme conjugated to the antibody cleaves a substrate to 
produce a colored precipitate at the location of the protein, or fluorescent detection, in which a 
fluorophore is conjugated to the antibody and can be visualized using fluorescence microscopy. The 
given protocol describes the first method, i.e. chromogenic detection.  
 
- Deparaffinise and rehydrate sections in xylol (4 x 5 min), 100% Ethanol (3 x 2 min), 96% 
Ethanol (2 x 2 min), 70% Ethanol (2 x 2 min) and PBS (1 x 5 min)  
- Perform heat-mediated antigen retrieval by boiling slides in the desired buffer. Either use 
Tris/EDTA (10 mM Tris Base, 1 mM EDTA Solution, 0.05% Tween 20, pH 9.0) or Sodium 
citrate buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 6.0). Therefore, remove the slides 
from the PBS and place them in a microwaveable vessel. Place the vessel inside the 
microwave. Set microwave to full power and wait until the solution comes to the boil. Boil for 
20 min from this point. If using a scientific microwave, program so that antigens are retrieved 
for 10 min once the temperature has reached approximately 98°C 
- Let slides cool down till room temperature 
- Wash in PBS (3 x 5 min) 
- Block endogenous peroxidase activity by incubating slides for 30 min in 0.3% hydrogen 
peroxide (Carl-Roth, Germany) diluted in PBS  
- Wash in PBS (3 x 5 min) 
- If primary mouse antibodies are used on mouse tissue, block unspecific bindings of secondary 
anti-mouse antibodies by incubating the slides in blocking solution (Immunologic, 
Netherlands) for 3 h at room temperature 
- Decant the blocking solution and apply the primary antibody over night at 4 °C diluted in 
blocking solution. Use a wet chamber to avoid drying-out of the slides 
- The next day, decant the primary antibody and wash in PBS (3 x 5 min) 
- VECTASTAIN® ABC (peroxidase) system (vectorlabs, USA) or EnVision® polymer 
secondary antibodies (Dako, Germany) are used to label primary antibody-antigen conjugates 
following the manufacturer recommendation  
- Wash in PBS (3 x 5 min) 
- Incubate the slides in either 3,3-Diaminobenzidine (Dako, Germany) or aminoethyl carbazole 
(Invitrogen, Germany) for 10 min in room temperature to visualize antibody-antigen 
conjugates 
- Counterstain with haematoxylin to visualize cell nuclei if desired  
- Dehydrate sections in 70% Ethanol (3 x 2 min), 96% Ethanol (3 x 2 min), 100% Ethanol (3 x 
2 min), xylol (4 x 5 min) 
- Mount slides  
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Appendix table 1: Clinical details of patients (chapter 3) 
 
MS type Gender 
Age in 
years Disease duration  
Post mortem 
delay Cause of death A CA CI blocks 
Progressive M 70 46 years 8h Cardiac arrest   2 2 17 
Secondary progressive M 49 25 years 8h Pneumonia   3   10 
Secondary progressive M 61 31 years 9h Unknown 1 1 1 15 
Relapsing-remitting M 50 17 years 5h Pulmonal cancer       4 
Primary progressive M 66 26 years 7h Ileus   2   14 
Primary progressive M                                                71 26 years 7h Pneumonia by aspiration       8 
Primary progressive M 41 14 years 7h Urosepsis, Pneumonia 4 1 1 9 
Progressive F 75 28 years 5h Cardio-pulmonary dysfunction       2 
Progressive F 81 64 years 5h Unknown       5 
Secondary progressive F 43 23 years 11h Subdural haematoma, pneumonia    3 2 8 
Secondary progressive F 67 42 years 9h Cardio-pulmonary dysfunction       4 
Secondary progressive F 81 59 years 7h Unknown       12 
Secondary progressive F 78 30 years 11h CVA relapse, dehydration   1   5 
Primary progressive F 56 19 years 6h Unknown     1 7 
Primary progressive F 88 25 years 8h Unknown       9 
Primary progressive F 76 19 years 9h Unknown       7 
Primary progressive F 77 41 years 9h Euthanasia       4 
Progressive F 77 48 years 11h Pneumonia, bleeding caused by duodenal ulcer     1 6 
not determined F 47 16 years 4h Cardio-pulmonary dysfunction       7 
not determined F 74 16 years 7h Shock, cause unknown       10 
not determined F 68 44 years 8h Cerebral vascular problems       4 
 
Abbreviations: male (M), female (F), hours (h); cerebrovascular accident (CVA) 
 
 
 
 
 
 
   
Appendix table 2: Clinical details of patients (chapter 4) 
 
 
MS type Gender 
Age in 
years Disease duration  
Post mortem 
delay Cause of death 
Autopsy 
          
Primary progressive F 72 10 years 12h Pneumonia 
Progressive F 84 35 years 1h Euthanasia 
Progressive F 84 35 years 1h Euthanasia 
Progressive F 70 30 years 7h Urinary tract infection 
Progressive M 66 26 years 8h Unknown 
Secondary progressive F 66 22 years 6h Unknown 
Primary progressive M 44 13 years 12h Unknown 
Biopsy 
          
isolated syndrom F 52 2 months not applicable not applicable 
isolated syndrom M 25 1.5 months not applicable not applicable 
isolated syndrom F 29 1 month not applicable not applicable 
isolated syndrom F 62 2 months not applicable not applicable 
Relapsing-remitting M 31 18 days not applicable not applicable 
Relapsing-remitting M 39 8 months not applicable not applicable 
 
 
 
 
 
 
 
 
 
 
  
 
Appendix table 3: List of antibodies 
 
Primary antibodies Manufacturer Host IHC mouse IHC human WB AGR 
Adenomatus Polyposis Coli (APC) Calbiochem; OP80 mouse 1:200   citrate 
Beta-Actin Sigma; A2066 rabbit   1:1000  
Glial fibrillary acidic protein (GFAP) Encore; RPCA-GFAP rabbit 1:1000  1:10.000 none 
Ionized calcium binding protein 1 (Iba1) Wako; 019-19741 rabbit 1:500   Tris/EDTA 
Oligodendrocyte transcription factor 2 (Olig2) Millipore; MABN50 rabbit 1:1000 1:1000  Tris/EDTA 
Proteo Lipoprotein (PLP) Serotec; MCA839G mouse  1:1200  none 
M3/84 antibody (MAC-3) BD Pharmingen; 553323 rat 1:500   Tris/EDTA 
Brain lipid binding protein (BLBP) Abcam; ab32423 rabbit 1:500 1:250  none 
Neuronal nuclei (Neu-N) Millipore; MAB377 mouse 1:1000    
HLA-DR (LN3) Abcam; ab49388 mouse  1:250  citrate 
       
Secondary antibodies      
 
Alexa-Fluor 488 Invitrogen; A11034 donkey 1:500 1:500   
Alexa-Fluor 568 Invitrogen; A11004 goat 1:500 1:500   
Biotinilated secondary antibody anti mouse Vector labs; BA-2000 horse 1:500    
Biotinilated secondary antibody anti rabbit Vector labs; BA-1000 horse 1:500    
HRP-conjugated anti-mouse Abcam; ab6728 rabbit   1:3000  
HRP-conjugated anti-rabbit BioRad; 170-5046 goat   1:3000  
  
 
Abbreviations: Immunohistochemistry (IHC), western blot (WB), antigen retrieval (AGR) 
 
 
 
 
  
 
 
Appendix table 4: List of primers 
 
  sense antisense bp AT 
HPRT (m) gct ggt gaa aag gac ctc t cac agg act aga aca cct gc 249 62 
PLP (m) tgg cga cta caa gac cac ca gac aca ccc gct cca aag aa 116 56 
CD11b (m) cca tga cct tcc aag aga atg c acc ggc ttg tgc tgt agt c 147 60 
GFAP (m) gag atg atg gag ctc aat gac c ctg gat ctc ctc ctc cag cga 381 60 
ADFP (m) gac ctt gtg tcc tcc gct tat  caa ccg caa ttt gtg gct c 157 60 
CST7 (m) gga gct gta ctt gcc gag c cat ggg tgt cag aag tta ggc 108 60 
LYN (m) gtg aca ttg tgg tgg cct tat acc att ccc cat gct ctt cta 105 61 
IFIT3 (m) agt gag gtc aac cgg gaa tct tct agg tgc ttt atg tag gcc a 188 60 
BLBP (m) gga cac aat gca cat tca aga ac ccg aac cac aga ctt aca gtt t 101 60 
PRKCD (m) cct cct gta cga aat gct cat c gtt tcc tgt tac tcc cag cct 181 60 
IGF1 (m) cta cca aaa tga ccg cac ct cac gaa ctg aag agc atc ca 155 60 
18s (h) caa ctt tcg atg gta gtc g cct tcc ttg gat gtg gta 110 58 
IGF1 (h) atg tct ttc agt tcg tgt gtg  gca ctc cct cta ctt gcg ttc 258 62 
FGF2 (h) atc aaa gga gtg tgt gct aac a cct gcc cag ttc gtt tca gtg 177 65 
PDGF (h) cca gcg act cct gga gat aga cgt cct ggt ctt gca gac ag 168 62 
SPP1 (h) ctc cat tga ctc gaa cga ctc cag gtc tgc gaa act tct tag at 229 65 
 
Abbreviations: mosue (m), human (h), base pair (bp), annealing temperature (AT) 
 
 
 
